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ABSTRACT 
Studies on a new ultrasound contrast agent: Strategies for increasing the population of 
nano bubbles and for encapsulation of Paclitaxel. 
Shweta Naidu Chitoor 
 
 
Paclitaxel (Taxol) is an anti-cancer drug obtained from the bark and needles of Taxus 
brevifolia. It is known for its unique mode of action and used for the treatment of breast 
and ovarian cancer. Also, paclitaxel shows very low solubility in water and is associated 
with a number of toxic side effects. The currently used formulation of paclitaxel with 
cremophor EL results in several hypersensitivity reactions. In order to tackle this 
problem, there is a need to develop targeted paclitaxel therapy for cancer treatment. 
Since, paclitaxel is highly hydrophobic, it can be incorporated in the hydrophobic core of 
vesicles such as SE61, a surfactant stabilized mixture of micro and nano gas bubbles.  
When ultrasound is transmitted in the body and encounters a medium with different 
acoustic impedance, such as a gas bubble, the backscatter is greatly increased, giving 
contrast enhancement. Ultrasound also causes the bubble to oscillate and break releasing 
any entrapped drug, for example at a tumor site. This helps in controlled and target drug 
release, preventing the drug action on normal healthy cells. An added advantage is that 
ultrasound facilitates drug uptake by increasing the permeability of the cell membrane. 
Nanobubbles can easily pass through the capillary walls of blood vessels in the targeted 
tumors enabling site specific delivery of drug. The gas core of SE61 contrast agent was 
xxv 
 
made up of perfluorocarbon (PFC) and stabilized by mixture of two surfactants- span 60 
(Sorbitan Monosterate) and TPGS (water soluble Vitamin E- nonionic surfactant).  
In the first part of the study, acoustic characterization of standard SE61 micro and 
nanobubbles were performed. The average diameter of standard SE61 microbubbles was 
2-2.3 µm and provided contrast enhancement between 18- 24 dB. Nanobubbles with 
mean diameter of 350-480 nm were separated from the primary mixture and provided 
contrast enhancement between 18-23 dB. The second part of the study involved studying 
the effects of changing salt concentration and surfactant ratios on the population of 
nanobubbles. Due to difficulty in counting the number of nanobubbles, the increase or 
decrease in the amount of nanobubbles produced were compared by means of turbidity 
measurement at 610 nm. From the salt study, nanobubble population was found to be 
highest at 387mM total sodium chloride with 80: 20 molar ratio of span 60: TPGS. In 
case of microbubbles, 262mM total sodium chloride concentration gave slightly higher 
maximum enhancement (28 ± 1.5 dB) compared to standard 650mM SE61 microbubbles 
( 25.72 ± 0.855 dB) at dose of 60 µl/L. From the surfactant study, 1: 0.43 (for 
nanobubbles) and 1: 0.25 (for microbubbles) molar ratio of span 60: TPGS were chosen 
as the ratio in newly formulated bubbles.  
The third part of the study involved encapsulating paclitaxel into the shell of the bubble 
by a direct loading method. The Paclitaxel encapsulation efficiency was compared 
between the newly formulated (from salt and surfactant study) and standard SE61 
bubbles using high performance liquid chromatography. When compared with 
microbubbles, paclitaxel loaded in standard SE61 microbubbles was 29.4% and in 
paclitaxel loaded newly formulated microbubbles was 10.98%. In case of nanobubbles, 
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formulation change did not affect paclitaxel encapsulation efficiency. The encapsulation 
efficiency of paclitaxel loaded into standard SE61 nanobubbles was 14.4% and in 
paclitaxel loaded newly formulated nanobubbles was 13.9%.  
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CHAPTER 1: OBJECTIVES OF THESIS 
 
The overall goal was to study a new ultrasound contrast agent SE61 which exhibited a 
mixed population of micro and nano surfactant stabilized gas bubbles and to study the 
effects of loading paclitaxel into it. The study was in two parts: a study of the effect of 
varying total salt concentration and surfactant concentration on SE61, and paclitaxel 
loaded SE61 contrast agents and studying of the efficiency of paclitaxel encapsulation 
into contrast agent by high performance liquid chromatography. 
Detailed objectives of the thesis are:  
1) Preparation of standard SE61 micro and nano surfactant stabilized gas bubbles. 
Perform size analysis and study the acoustic behavior using dose responses, and stability 
of bubbles.  
2) Increase the nanobubble population by varying parameters used in the preparation: 
• Total sodium chloride concentration  
• Surfactant concentration- D-alpha tocopheryl polyethylene glycol 1000 succinate, 
(TPGS) 
3) Study the effect of paclitaxel loading in micro and nanobubbles on the echogenecity 
and stability of the agent 
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4) Study the efficiency of paclitaxel encapsulation in contrast agent by high performance 
liquid chromatography. 
Micro and nanobubbles where prepared using two surfactants – Span 60 and D-α-
tocopheryl polyethylene glycol 1000 succinate. For the first part of study, the total 
sodium chloride concentration was varied keeping span 60: TPGS molar ratio same as 
standard SE61.  This was done to analyze which concentration of total sodium chloride 
gave higher nanobubble population. Also, the effect of varying total sodium chloride 
concentration on microbubble echogenecity and stability were studied.  
For the second part of study, the TPGS concentration was varied keeping span 60 and 
total sodium chloride concentration same as standard SE61. Also, increase or decrease in 
nanobubble population was studied at each TPGS concentration level.  
Paclitaxel was directly loaded into the hydrophobic region of the bubble. Paclitaxel 
encapsulation efficiency was compared between the newly formulated (from salt and 
surfactant studies) and standard SE61 bubbles by high performance liquid 
chromatography.  
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CHAPTER 2: BACKGROUND 
 
Ultrasound imaging has become a successful and well established diagnostic technique 
for clinical decision making [1]. This is because ultrasound imaging is non-invasive [2] , 
less expensive[3] and provides real time images of soft tissue structures such as heart and 
blood flow without the use of ionizing radiation [3].Ultrasound waves can be used for 
tumor imaging and controlled drug release by focusing ultrasound beam at the tumor site 
[4].  
Over the last few decades a lot of hard work is being dedicated towards improving the 
image quality by modifying the transducer or by image processing technologies. But still 
ultrasound images lack contrast to identify metastatic lesions in soft tissues and 
abnormalities in body cavities and vessels [5]. To deal with this problem ultrasound 
contrast agents have been developed which when injected intravenously provide contrast 
enhancement thus improving image quality. Also, these contrast agents can be used for 
targeted drug delivery by encapsulating the drug in the agent.  
The introduction gives brief description on physics of ultrasound and effects of 
ultrasound on contrast agents.  Also, information about the pharmacology of paclitaxel, 
the drug being loaded into the bubble and its therapeutic potential is being discussed in 
detail. Also, the advantages of using nanobubbles containing encapsulated drug in 
targeted cancer treatment are mentioned in the background. 
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2.1 Introduction about ultrasound 
Ultrasound waves are sound pressure waves with frequencies greater than 20 kHz usually 
generated by piezoelectric transducer [2]. The Human ear can hear in the frequency range 
of 20Hz to 20 kHz [3]. In Diagnostic ultrasound, frequency range from 2-12 MHz [6] is 
used to provide real time images of body tissues such as for  abdominal and 
gynecological applications. Therapeutic high frequency focused ultrasound operates 
around 1 MHz [7] and is used for break kidney stones and heal damaged tissues in the 
body. Higher ultrasound frequencies provide poor penetration in deeper tissues as lose 
their signal strength quickly [6]. However, image resolution increases with the increase in 
ultrasound frequency improving the diagnostic potential by the physician. Attenuation of 
ultrasound waves at higher frequencies occurs due to scattering of wave or due to 
absorption where a portion of ultrasonic wave is absorbed by tissue  and by conversion to   
heat [7].  
2.1.1 History of ultrasound 
The evolution of ultrasound as an image modality dates back in 19th century when the 
scientists wondered about the use of ultrasound in medicine. In 1826, Jean-Daniel 
Colladon, Swiss physicist studied the compressibility of liquids and determined the speed 
of sound using underwater bell [8]. In 1880, Pierre and Jacques Curie discovered a 
phenomenon called “piezoelectricity” using quartz crystals which generated electric 
charge when pressure was applied to them [8]. Conversely, when rapidly changing 
electric potential was applied to the crystal, it caused crystal to vibrate and produce 
ultrasound waves [8]. This marked the basis for the development of modern day 
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ultrasound transducer although many modifications have been made over the last few 
decades for improving the image quality.  
 
Later, ultrasound was used for military applications in quest for naval superiority. In 
1915, Paul Langevin and Chilowsky developed a hydrophone which generated and 
received ultrasound waves [8] which helped in the detection of ice bergs in sea. Ludwig 
and Struthers, scientists at Naval medical research found that the mean velocity of 
ultrasound in soft tissue was 1540m/s [8]. In 1950’s Ian Donald used A-mode ultrasound 
machine to differentiate tissues in excised fibroids and ovarian cysts[8]. Later use of 
ultrasound was extended to cardiac evaluation and blood flow recordings. A major 
transition was experienced after 1975, when real time B-mode imaging and pulse 
Doppler systems were introduced [9]. With the invention of Doppler color-flow mapping 
and Power Doppler in recent years, the scope of applications of ultrasound has widened 
making ultrasound imaging a successful and popular image modality among surgeons 
and physicians. 
2.1.2 Physics behind ultrasound  
Ultrasound waves are longitudinal mechanical waves requiring a physical medium for 
propagation [10]. The wave propagation occurs by longitudinal motion (compression and 
rarefaction) and not by transverse motion (side by side). Ultrasound waves travels in 
waves that emanate from a source [7]. The high rests and low troughs represent 
amplitude values of the wave which corresponds to peak compression and peak 
rarefaction values [7].  
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Frequency of the ultrasound wave is related to the time period represented by equation 
2.1 
f = 1/ T     (Eq2.1) 
Where f is the frequency of ultrasound wave in Hz and T is the time for one cycle to 
occur in seconds. 
The speed of sound (c in m/s) is related with the frequency of the ultrasound wave and is 
represented by the equation 2.2. 
                                                       c = λ* f      (Eq2.2) 
where λ is the wavelength of the wave in meters [7] 
For medical applications, the propagation speed c in tissues is assumed to be 1540m/s [7]. 
Two different modes are used are used in medical ultrasound as shown in figure 2.1. One 
mode is to continuously excite the ultrasonic transducer with a sine wave with constant 
amplitude called continuous wave ultrasound (CW ultrasound) [7]. Another mode is 
called the pulse wave ultrasound mode where the transducer is exited with very short 
electrical signals waiting for some time and again repeating the electrical shocking [7]. 
Pulse repetition frequency is an important parameter to be considered in pulse wave 
ultrasound mode. 
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Figure 2.1: Representation of continuous and pulsed ultrasound waves [7] 
 
The magnitude of Acoustic impedance is defined as the product of density of the material 
(ρ) and speed of sound in the material (c) [7] and is represented in the equation 2.3. The 
unit for acoustic impedance is rayl (kg/m2s) and density of material in kg/m3. 
                                                             Z= ρ * c      (Eq. 2.3) 
The propagation of ultrasound is influenced by changes in the acoustic medium [10]  
Pressure reflection coefficient R is described by the equation 2.4 
R = (Z2 – Z1) / (Z2 + Z1) [10]      (Eq2.4) 
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Negative value of reflection coefficient indicates 180 degrees phase shift between the 
transmitted and reflected ultrasound wave. 
Acoustic intensity I can be computed using the formula described in equation 2.5  
I = P2 / 2ρ0 c0      (Eq2.5) 
where P is the pressure amplitude of the wave in Pascals and acoustic intensity is in 
W/m2 [10] 
As ultrasonic waves propagate through homogenous media attenuation occurs with 
distance due to acoustic absorption [10] and is described in equation 2.6. 
                                                    I= I 0 e-2α1 Z       (Eq2.6) 
where I0 is the initial intensity in W/m2 and α1 is the amplitude absorption coefficient of 
the medium  [10] 
For inhomogeneous medium, attenuation occurs due to acoustic scattering although for 
many tissues scattering is smaller than absorption [10].Tissues have higher attenuations 
that increase linearly with frequency [10]. When ultrasound wave propagates in tissue, a 
mechanical strain is induced due to stress where there is relative change in dimension or 
shape of the body termed as ultrasound –induced cavitation [7]. When ultrasound waves 
hits the bubble , it oscillates at high ultrasonic pressure levels and finally collapses due to 
cavitation [7]. 
2.2 Ultrasound contrast agents  
Ultrasound imaging lacks ability to differentiate between tissues having similar acoustic 
properties[11]. The solution to this problem is use of ultrasound contrast agents which 
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when, injected intravenously improve the contrast between the two tissues by changing 
the reflection coefficient [11]. Ultrasound contrast agents could be in the form of solid 
particles in suspension, liquid droplets (emulsion), gas bubbles, encapsulated gases or 
liquids [12]. When ultrasound hits the gas bubbles, the wave will be reflected at the 
surface of the bubble because of large difference in acoustic impedance between the 
surrounding medium and gas inside the bubble [1]. They increase the backscattered 
signal giving contrast enhancement in the image thus improving the  image quality [11]. 
They also  enhance the resolution of images and enhance the diagnostic power of the 
physician [13].  
During the initial years of contrast agent development, the main challenge most scientists 
faced was to produce small microbubble (< 8 µm) that could pass through the lung 
capillary circulation and were stable enough to reach the left heart after an intravenous 
injection [1]. An ideal contrast agent should be non-toxic, easily injected through 
intravenous route and stable for recirculation[14]. Also, it should be able to traverse the 
capillary and pulmonary circulations to provide view of the target tissue or deliver drug at 
particular site [14]. The bubbles must be less than 8µm in diameter in order to effectively 
pass through the lung capillaries [15]. 
As shown in figure 2.2, different gases can be used in preparation of gas core 
microbubbles such as air, perfluorocarbon and sulfur hexafluoride. Also, the shell 
composition of the bubble can surfactant stabilized or made of biocompatible polymers or 
protein like albumin. The size of the microbubbles is a very important parameter 
considered during characterization of contrast agents. In the figure 2.2, the size of the 
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microbubbles shown is less than 4 µm which can easily pass through the capillaries and 
ideal for medical imaging.  
 
 
Figure 2.2: Microscopy of ultrasound contrast agent[16] 
 
2.2.1 Targeted drug release using contrast agents  
Ultrasound contrast agents can act as drug delivery vehicle to particular sites enabling 
targeted drug delivery. Targeted drug delivery is very important when the drug has toxic 
side effects such as anti-cancer drugs. Also the drug release can be controlled by the 
ultrasound beam reducing the toxic side effects of anti-cancer drugs used in cancer 
treatment.  
The conventional cancer chemotherapy has several side effects associated with the 
procedure. Therefore targeted drug delivery is particularly essential in cancer treatment 
where the normal healthy cells are unaffected with the drug and the tumor site receives 
the drug for treatment. This will facilitate in providing drug at the tumor site where cells 
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may have survived surgery, thus preventing regrowth and metastasis of tumor [17]. 
Targeted drug delivery minimizes toxic side effects, lower the required drug dosage 
amounts and decrease costs for the patients [3, 18, 19] 
Gas filled microbubble are more compressible than water or tissue [16] and undergo 
volumetric oscillation consisting of compression which occurs during pressure peaks and 
expansion which occur during pressure nadirs of the ultrasound wave [16]. The 
destruction caused due to the ultrasound beam causes collapse of microbubbles producing 
a high amplitude response [3, 20]. This violent microstreaming encourages diffusion of 
drugs into tissues and lesions when the contrast agent is encapsulated within the drug [3, 
21].  
Also, ultrasound increases membrane permeability by shear stress and causes entry of the 
drug into cells and tissues [3] shown in figure 2.3. Ultrasound improves transfection by 
causing transient non-lethal perforation of capillary and cell membrane by cavitation [3]  
shown in figure 2.3. Ultrasound can change the chemical property of the drug such as 
hematoporphyrins which, when activated by ultrasound causes cancer cell death [3, 22]. 
This is a very important use of ultrasound which is currently being exploited in cancer 
research.  A flow chart showing different applications and mechanisms of ultrasound 
mediated drug / gene delivery are shown in figure 2.3.  
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Figure 2.3: Representation of mechanisms and applications of focused ultrasound beam in drug/ gene 
delivery [23]. 
 
Delivery to specific target sites can be further aided by attaching ligands into the 
membrane of gas bubbles that interact with the target receptors on the cell membrane[3]. 
As shown in figure 2.4, drugs can be directly attached to the membrane surrounding the 
gas bubble represented as A , or can be imbedded within the membrane materials (B), can 
be made to bind non-covalently to the surface of bubbles (C) or loaded in the interior of 
the gas bubble (D) or hydrophobic drugs that can be incorporated into a layer of oily 
material which is later surrounded by stabilizing membrane (E) [3, 24]. 
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Figure 2.4: Schematic representation of different ways microbubble can carry drugs for targeted delivery 
[3, 24] 
Ultrasound energy can help agents such as drugs to penetrate through various tissues such 
as skin and even blood clots [3, 25]. Gas microbubbles suspended in liquid are extremely 
efficient ultrasound reflectors making them useful as ultrasound contrast agents [3]. 
Coated microbubbles are more stable in the bloodstream because the shell protection the 
gases from getting diffused into the blood [3].  
2.2.2 Gas core of the bubbles  
The stability of microbubbles contrast agents can be improved by using gases with 
relatively low diffusion coefficients and low solubility in water and blood [16] The most 
common gases used for this purpose include perfluorocarbon (such as octafluoropropne 
[C3F8] and decafluororbutane [C4F10]) [16]. Second generation microbubbles contain 
perfluorocarbon as the gas core rather than air which permits a longer window of time to 
14 
 
image the patients[3]. Previous studies from the laboratory showed that certain mixtures 
of non-ionic surfactants produced stabilized micron sized bubbles, particularly a mixture 
of span 60 and tween 80, which is designated by us as ST68 [13]. It was also shown  that 
perfluorocarbon filled ST68 micro bubbles produced higher vascular enhancement (26.1 
dB for dose of 0.1ml/kg) than air filled ST68 microbubbles (18.3 dB for dose of 
0.13ml/kg) [14]. Also, the enhancement for ST68- PFC microbubbles lasted for 8 min 
than ST68-Air micro bubble which showed less stability of less than 2 min [14]. 
2.3 Surfactants used for bubble preparation  
Two non-ionic surfactants are used for preparation of SE61 microbubbles and 
nanobubbles.  The procedure for micro and nanobubble preparation was similar to the 
Standard laboratory procedure mentioned in [5] for ST68 with slight modifications. The 
patent protecting and describing the invention in the laboratory is mentioned in reference 
[26]. Investigations into developing an agent with a more biocompatible mixture of 
surfactants, and one with a higher proportion of nanobubbles, lead us to employ TPGS in 
the place of Tween 80, and the resulting agent is designated SE61. This introduction 
gives a brief description of the chemical structure, uses and properties of the two 
surfactants used in the preparation of SE61 micro and nanobubbles. 
2.3.1 Span 60 (Sorbitan Monostearate) 
Span 60 is a synthetic non-ionic emulsifier used in small concentrations as food additive 
[27]. It consists of partial esters of stearic acid and mixed anhydrides of sorbitol [27]. In 
simpler words, Span 60 is an ester of sorbitan and stearic acid. The IUPAC name of Span 
60 is [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]octadecanoate. The 
chemical structure of Span 60 is shown in (Figure 2.5). Span 60 has molar mass of 
15 
 
430.62g/mol with molecular formula as C24H46O6. Apart from being used as an 
emulsifier, Span 60 is used as flavor-dispersing agent in food and beverages industry 
[28]. It is also used in some pharmaceutical creams for topical use [28]. Apart from that 
Span 60 is used in bread, cakes, whipped vegetable oil and fat-water emulsions [28]. The 
insolubility and waxy nature of Span 60 makes it unsuitable for parenteral administration 
[28].  
 
Figure 2.5: Structure of Span 60 obtained from Sigma Aldrich website( PubChem Substance Id: 24899728 
and Substance summary SID 24899728) 
In a mice study Span 60 was given at dose levels of 0·5, 2·0 or 4·0% of the diet for 80 
weeks where no carcinogenicity was observed at any dose levels [28]. But enlargement of 
kidneys and higher incidence of nephrosis was observed at 4% Span 60 diet level [28].   
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2.3.2 TPGS 
D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) is a water- soluble succinate 
ester of vitamin E [29]. TPGS is an amphiphilic compound having lipophilic alkyl tail 
and hydrophilic polar head [29, 30]. The chemical structure of Vitamin E TPGS and 
Vitamin E are shown in figure 2.6. It melts at 37- 41 degree Celsius and is heat stable 
under temperature 200 degree Celsius [31]. TPGS improves the drug encapsulation 
efficiency due to its bulky structure and large surface area [29, 30]. TPGS is synthesized 
from α-tocopherol (vitamin E) by grafting to polyethylene glycol (PEG) oligomer 
through succinate diester linker [32]. TPGS 1000 where 1000 denotes molecular weight 
of polyethylene glycol chain [32]. 
TPGS is approved by Food and[32] Drug Administration as a drug solubiliser in oral, 
parenteral, topical and nasal therapies [32-34]. It is an excellent emulsifier, solubiliser 
and increases the bioavailability of hydrophobic drugs [35, 36]. TPGS is a used in 
fabricating nano/microparticles with high drug entrapment efficiency [35, 37, 38].   
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Figure 2.6: Structures of Vitamin E and Vitamin E TPGS [31] 
The lipophilic alkyl tail (polyethylene glycol) and hydrophilic polar head portion 
(tocopherol succinate) are bulky and have large surface area [31]. Vitamin E TPGS is 
readily absorbed in the gastrointestinal tract (GI) and enhances the cytotoxicity of 
paclitaxel and doxorubicin by inhibiting P-glycoprotein in the intestine [31, 39]. Non-
ionic surfactants are more hydrophobic and less toxic to biological membranes, 
enhancing the capability to dissolve poor water solubility drugs like paclitaxel [40, 41]. 
2.4 Paclitaxel (drug)  
Paclitaxel is an antineoplastic agent derived from bark of Pacific yew Taxus brevifolia 
[42]. It is an effective anticancer drug used as a single agent or in combination with other 
agents for the treatment of breast, ovarian and non-small-cell lung cancer [42, 43]. 
Paclitaxel shows very low aqueous solubility of < 0.03 mg/ml [42, 44] and does not 
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contain any functional groups that can be ionized by altering pH [42]. It is white to off-
white crystalline power and is highly lipophilic[45]. In the blood stream, paclitaxel is 
extremely protein bound ( 95-98%) [17] [46]. Also, paclitaxel has shown dose-dependent 
antiangiogenic activity as per the experiments conducted using chick chorioallantoic 
membrane [17, 47-50]. Paclitaxel is a highly functionalized diterpenoid with molecular 
formula of C47H51NO14 and molecular weight of 853.9 Da [45, 51]. 
2.4.1 History of development of paclitaxel as anti-cancer drug  
Paclitaxel was discovered during a broad screening programme for natural products 
conducted by National Cancer Institute in 1960s [45]. The crude extract from bark of 
Taxus brevifolia showed antitumor activity against several cancerous cell lines which led 
to its popularity [45, 52]. In 1963, Wall and Wani demonstrated cytotoxic activity against 
L1210 and P388 leukemia’s, sarcoma 180 and B16 melanoma using crude extract from 
Taxus brevifolia [53]. In 1971, structural identification of paclitaxel as active constituent 
in the crude extract was performed [52, 53]. In 1983, Phase 1 studies were initiated and 
1986, hypersensitivity reactions due to paclitaxel treatment was observed in the patients 
[45]. Paclitaxel was proven effective against ovarian cancer in 1989, breast cancer in 
1991 and for non-small cell lung cancer in 1992 [45]. United States Food and drug 
administration approved Paclitaxel for refractory ovarian cancer in 1992 and for 
metastatic breast cancer in 1994 [45]. Paclitaxel popularity was due to extraction from 
plant source, unique mechanism of action and being effective anti-cancer drug for a wide 
range of tumors.  
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2.4.2 Structure of Paclitaxel 
Paclitaxel is a diterpene alkaloid with a complex chemical structure shown in Figure 7. 
The chemical name of paclitaxel is 5b, 20-epoxy-1, 2a, 4, 7b, 10b, 13a-hexahydroxytax-
11-en-9-one-4, 10-diacetate-2-benzoate 13 ester with (2R, 3S)-N-benzoyl-3-
phenylisoserine [45]. Paclitaxel structure consists of 14-membered taxane ring linked to 
an ester side chain at position 13 [53]. The detailed chemical structure of paclitaxel is 
shown in figure 2.7. Also, presence of hydroxyl group at 2” position of ester side chain 
increases cytotoxic activity of the drug [45, 54]. Also, the side chain is very important for 
anti-tumor activity because analogs of Paclitaxel which do not possess this side chain are 
not cytotoxic [55, 56]. Paclitaxel is stored at or below -20◦ C and has molecular weight of 
853.91.  
 
Figure 2.7: Chemical structure of Paclitaxel [51]  
 
2.4.3 Original paclitaxel formulation vehicle  
Paclitaxel (6 mg/ml) for intravenous infusion is formulated in a 1:1 v/v mixture of 
Cremophor EL and dehydrated alcohol [42]. Cremophor EL is polyethoxylated castor oil 
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used as a formulation agent for Paclitaxel drug delivery. Intravenous route for Paclitaxel 
administration is not a safe route because there are several risks associated with this 
technique such as catheter related infection, potential thrombosis and presence of 
particulate matter in the intravenous infusion formulation [42]. Also, severe 
hypersensitivity reactions, hypotension and vasodilation have been observed in patients 
treated with paclitaxel with cremophor EL [42, 57]. During those days, it was not known 
whether the observed effects were due to paclitaxel itself or the due to the formulation 
vehicle used during intravenous injection. In order to tackle the problem of 
hypersensitivity reactions, patients were pretreated with mandatory premedication with 
corticosteroids, diphenhydramine and H2- receptor antagonists before treating with 
paclitaxel [45].  
Later on several studies were conducted to study biological effects of cremophor EL 
which revealed important results. Cremophor EL resulted in anaphylactic hypersensitivity 
reactions characterized by dyspnoea, flushing, rash, chest pain, tachycardia, hypotension, 
angio-oedema, and generalized urticarial (hives) [58]. However, it blocks P -glycoprotein 
drug efflux pump and helping in increasing delivery of paclitaxel to target tumor cells by 
reversing multi-drug resistance phenomenon [59]. 
Since paclitaxel is highly hydrophobic, it can be incorporated in the hydrophobic core of 
the SE61 surfactant stabilized micro and nanobubbles. This helps in eliminating use of 
cremophor EL vehicle and reduces the problems of conventional paclitaxel 
chemotherapy. 
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2.4.4 Mechanism of action  
Paclitaxal inhibits cell cycle in late G2 mitotic phase [60, 61]. Guanosine triphosphate 
associated proteins are required for tubulin assembly under normal conditions which are 
not necessary when paclitaxel is used [60]. Paclitaxel promotes polymerization of tubulin 
dimers to form unusually stable microtubules and prevent depolymerization [45, 61, 62].  
The binding site for Paclitaxel is N-terminal 31 amino acids of β – subunit of tubulin in 
the microtubule [45, 63]. Paclitaxal disturbs the equilibrium between microtubule 
assembly and disassembly and disrupt the formation of normal spindle during metaphase 
stage [61, 64]. The microtubules formed are dysfunctional causing death of cancer cells  
[43, 45].  The mechanism of action of paclitaxel is shown in figure 2.8 showing the 
formation of ultra stabilized microtubules.  
 
Figure 2.8: Unique mode of action of Paclitaxel [45, 61, 62] 
As shown in figure 2.9, paclitaxel shows direct cytotoxicity by stimulating macrophages 
and killing the tumor cells. Also, indirect way of tumor cell death by paclitaxel occurs by 
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inducing secretion of cytokines which further activates dendritic cells, natural killer cells 
and cytotoxic T lymphocytes [65]. 
 
 
Figure 2.9 : Paclitaxel exhibiting direct and indirect cytotoxicity against tumor cell [65]. 
2.4.5 Pharmacology of paclitaxel 
Paclitaxel binds to proteins in plasma, tissues and tubulins  [66]. More than 90% of the 
paclitaxal rapidly binds to plasma proteins [51] [67, 68]. Paclitaxel shows affinity for 
distribution in specific tissue types such as kidney, lung and spleen which have the 
highest tissue concentrations [66, 69, 70]. Paclitaxel metabolism is due to oxidative 
metabolism and biliary excretion, only 5-10% is renally eliminated [66, 71]. The main 
hepatic metabolites detected are 6α-hydroxypaclitaxel (major metabolite), p-
hydroxyphenyl-C3’-paclitaxel (minor quantities), and dihydroxypaclitaxel (barely 
detected) [72, 73].  
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2.5 Cancer  
2.5.1 Multi-drug resistance and p-glycoprotein 
There are several problems associated with conventional cancer chemotherapy such as 
drug solubility, narrow therapeutic index of drug and P-glycoprotein efflux transporter 
specificity [40]. Multi-drug resistance has posed serious problems in targeted cancer 
treatment. Multidrug resistance (MDR) is simultaneous cellular resistance to a range of 
drugs which are not related  [74].  
P-glycoprotein is a 170kDa plasma membrane glycoprotein [74] drug efflux pump 
responsible for multidrug resistance phenomenon occurring during cancer treatment [75]. 
In humans, P-glycoprotein is encoded by MDR1 and MDR3 (multi-resistance genes) out 
of which MDR1 is associated with multi- drug resistance phenotype [76-78]. It consists 
of  1276- 1280 amino acids with each half containing site for nucleotide binding and 
hydrophobic regions [74]. A structure of P-glycoprotein is shown in Figure 2.10 where 
the 2 ATP binding domains plays important role in drug efflux reducing the intracellular 
concentration.  
P-glycoprotein is an extrusion pump specific to a broad range of substrates such as anti-
cancer drugs [79, 80]. It causes efflux of anti-cancer drugs out of the cells decreasing 
their concentration in cells and their cytotoxic effect on the targeted tumor cells [79, 80].  
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Figure 2.10 : Structure of P-glycoprotein efflux transporter with two ATP binding domains required for 
drug efflux [81] 
P-glycoprotein inhibits the drug permeability and expels drug molecules back into 
gastrointestinal lumen limiting absorption of the drug [40]. Also, p-glycoprotein 
influences the excretion of the drug by affecting both biliary and renal tubular functions 
[40]. In tumor cells, expression of P-glycoprotein causes multi-drug resistance limiting 
the pharmacological response [40]. In the past, a lot of research work has been done 
towards increasing the bioavailability of anti-cancer drugs in tumor cells by inhibiting P-
glycoprotein transporter directly [40]. Other approaches include development of 
formulations that allow drug to bypass the P-glycoprotein transporter or agents which are 
non-P-glycoprotein substrates [40].  
Surfactants such as Tween 80, Cremophor EL, TPGS modulate efflux pump by 
competitive inhibition of substrate binding, alteration of membrane fluidity and inhibition 
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of efflux pump ATPase activity [29, 39, 82]. D-α-tocopheryl polyethylene glycol 1000 
succinate (TPGS) modulates ABC-transporter P-glycoprotein activity by inhibition of 
efflux pump ATPase activity [39, 82, 83]. 
2.5.2 Tumor microenvironment 
In the case of solid tumors, conventional chemotherapy alone is the seldom curative [23, 
84].  The anticancer drugs are useful for killing tumor cells grown in monolayer cultures 
[23, 85]. However, they cannot kill all tumor cells that later develop into tumor in vivo 
[23, 85]. The tumor microenvironment is characterized by abnormalities in the 
vasculature and extracellular matrix responsible for insufficient delivery of drugs at the 
targeted site [23, 86]. There are abnormalities in vasculature such as blood vessels being 
leaky and possess large gaps between the endothelial cells [23, 87]. Leakiness of tumor 
blood vessels is due to open pores of sizes range from 380nm to 780nm at certain 
interendothelial junctions[88, 89].  The vasculature is disordered in regard to spatial 
distribution, random interconnections and abnormal length and diameter of microvessels 
[23, 86, 90]. 
In the blood flow in the tumor cells is further made worse by proliferating tumor cells 
which generate solid pressure on the vessels [23, 90]. Due to a lack of functional 
lymphatics, there is increase in the interstitial fluid pressures in tumor cells [23]. Apart 
from the poor organization of tumor vasculature, there is reduced delivery of oxygen and 
build up of metabolic products such as carbonic acids and lactic acid which reduce the 
extracellular pH [23, 85]. Nano-sized contrast agents are useful in imaging tumors as they 
provide  higher tissue extravasation rate causing high number of agents passing through 
the vessels in the targeted tumor  [88].  The tumor vasculature exhibits enhanced 
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permeability and retention effect causes retention of nanoparticles that are smaller than 
pore size which makes the development of nano-sized contrast agents of immediate 
importance [88, 91, 92]. The phenomenon of enhanced permeability and retention effect 
is shown in figure 2.11. 
 
Figure 2.11 : Normal tissue and tumor vasculature being compared where tumor tissue exhibits enhanced 
permeability and retention effect [93]. 
2.5.3 Angiogenesis  
Angiogenesis is a process where growth of new capillary blood vessels occurs [94] which 
plays a important role in development of cancer. Without angiogenesis, tumor cells do 
not enter into circulation and are limited to a very small size [94]. A change in the 
angiogenic balance between pro-angiogenic growth factors (VEGF, FGFs) and 
angiogenesis inhibitors (TSP-1) is responsible for angiogenesis progression [95-98]. 
Oxygen consumption by neoplastic cells and endothelial cells and poor oxygen delivery 
causes low oxygen concentration called hypoxia in tumor cells [99]. Vascular endothelial 
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growth factor (VEGF) is an inducer of angiogenesis and is responsible for endothelial 
cell proliferation [100, 101]. VEGF is produced due to hypoxia- inducible factor-1 
released by tumor cell in response to decrease in oxygen concentration (hypoxia) [100, 
102-105]. High VEGF expression allows tumor cells to enter blood stream and reduce the 
delivery of anti-cancer drugs for cancer treatment [90, 99, 106, 107]. Anti-angiogenic 
therapy inhibits endothelial cell proliferation or cause apoptosis of these cells in the 
tumor [94]. 
2.5.4 Paclitaxel and apoptosis  
The time course for apoptosis induced by paclitaxel was conducted in vivo in murine 
model and in patients undergoing paclitaxel chemotherapy [108-111]. In murine model, 
peak of apoptosis was observed within 24 hours and in clinical studies, peak was 
observed within 48 hours [108, 111]. However, the continuation of apoptotic response 
after initial intravenous push of paclitaxel in murine model was until 72 hours and in 
clinical studies, it continued until 96 hours [108, 111]. 
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CHAPTER 3: MATERIALS AND METHODS 
 
 
3.1 Materials used  
3.1.1 Surfactants 
Two non-ionic surfactants were used for preparing the micro and nanobubbles. Span 60 
(sorbitan monostearate) (S7010-1KG, batch # 010M0128) was purchased from Sigma 
Aldrich (St.Louis, MO) and used without purification. Eastman Vitamin-E TPGS ( d- 
Alpha Tocopheryl polyethylene glycol 1000 succinate)  NF grade was purchased from 
Eastman ( Llangefni, Anglesey, United Kingdom) (batch # 78971100) and used without 
purification. 
3.2.2 Buffer 
PBS (0.1M) was used as the buffer for preparing and testing the bubbles.  
Table 3.1: PBS ingredients 
Name of the chemical  Specifics Quantity (g) 
Sodium chloride  (S5886-1KG,  Batch # 078K01281) Sigma 
Aldrich (St.Louis, MO) 
8.01 
Sodium phosphate 
dibasic 
(S0876-1KG,  Batch # 075K0167)  Sigma 
Aldrich (St.Louis, MO) 
1.15 
Potassium  
phosphate monobasic 
( P5655-500G, Batch # 084K0175) Sigma 
Aldrich (St. Louis, MO) 
0.2 
Potassium chloride  (P-4504-500g, Batch # 31K0157) Sigma 
Aldrich  (St. Louis, MO) 
0.2 
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The above chemical were weighed out and transferred to 1L standard flaks and made up 
to 1L with distilled (DI) water. The pH was adjusted to 7.4 using 1M NaOH and HCl as 
required followed by filtration using 0.22µm GV Durapore membrane filter (lot # 
R6AN42605) purchased from Millipore.  
 3.1.3 Drug  
Paclitaxel (Cat No.P-9600, Lot ASM-113) was purchased from LC Laboratories 
(Woburn, MA) and used without purification.  
3.1.4 Other chemicals 
Octafluropropane (99.9%) was purchased from American Gas Group (lot # 0327BD09, 
Toledo, OH) and used after passing through passing through a 0.22µm filter (Nalgene, 
Rochester, NY). Acetonitrile HPLC Grade (CAS no. 75-05-8) was purchased from Fisher 
Scientific (Fair Lawn, New Jersey) was used without further purification. Ethyl Acetate 
HPLC Grade (CAS 141-78-6, Lot no. 032371) was purchased from Fisher Scientific (Fair 
Lawn, New Jersey) was used without further purification. Thermo scientific Nalgene 0.2 
µm syringe filter (Cat. No. 195-2520, Lot no. 1041670) were purchased from Fisher 
scientific, Newark. 1 ml vial with cap fisher brand (Cat. No. 03-391-23) were purchased 
from Fisher scientific were used during HPLC. Regular 3ml sterile luer tip syringes (Lot 
no. 006004) were purchased from Tyco healthcare (Mansfield, MA) used for injecting the 
extracted paclitaxel in the 1ml vial during HPLC sample injection.  
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3.2 Methods  
Ultrasound contrast agents were prepared using the Standard Operating Procedure (SOP) 
followed in the laboratory. The United States patent on “Surfactant stabilized 
microbubble mixtures, process for preparing and methods of using the same” with patent 
# 5352436 was used with preparation of bubbles with some changes [26]. 
3.2.1 Standard micro and nanobubble preparation 
The SOP for preparing the surfactant stabilized micro and a nanobubble is explained in 
the appendix B.1.  Briefly, calculated amounts of Span 60, TPGS, and sodium chloride 
were placed in a 300 ml beaker and 50 ml of PBS is added with pH 7.4.   The mixture 
was first heated with constant stirring until the span 60 and TPGS completely dissolved. 
Then the mixture was autoclaved. The mixture was cooled with continuous stirring to 
enable proper mixing of the surfactants and to decrease the particle size of span 60 that 
drops out of solution upon cooling.  
The beaker was kept in ice and octafluoropropane was used to purge the mixture.  A 
pipette tip was added to the exit tube of the gas cylinder and placed in the surfactant 
solution to allow a slow (50 ml/min) stream of gas to bubble through.  Later the 1000 µl 
pipette tip was placed above the solution which was then sonicated for 3 min at 110 W. 
with a sonicator ( Misonix Inc. Farmingdale, NY) employing a CL4 tapped horn probe 
with 0.5” tip shown in figure 3.1. 
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Figure 3.1: Photo of the Paclitaxel loaded SE61 being sonicated at 110W for 3 min using 
octafluoropropane. The SE61 mixture (B) was placed in ice (A) and covered with foil to hold the tip above 
the solution. The digital wattmeter was adjusted to 110W (C) and sonication was performed for 3 min 
(adjusted using instrument D). The pipette tip is connected to exit of gas cylinder and the pipe carries the 
octafluoropropane gas (E).  
 
The sonicated mixture was poured into a (4oC) separation funnel (A) and 50 ml of 4oC 
PBS was added to the funnel. This was the first wash with PBS.  The bubbles were 
allowed to separate and after 45 min, 25 ml of solution from the bottom of the separating 
funnel was discarded and 50-75 ml of the solution is transferred to a second cold (4oC ) 
separation funnel (B). Again both the funnels are washed with 50 ml of cold PBS which 
was considered as the second wash shown in figure 3.2. After 45 min, 50 ml of the 
solution was discarded from both the funnels and fresh 50 ml of cold PBS was added to 
each funnel. This was the third wash with PBS. Finally after a waiting period of 45 min, 
C 
B 
A 
D 
E 
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from funnel B (containing nanobubbles) 25 ml was discarded and 10 ml was collected in 
a 50 ml centrifuge tube. This is the standard nanobubble preparation.  The solution from 
funnel A separated into three distinct layers, a lower later containing unused surfactant, a 
middles, viscous layer containing microbubbles and an upper layer containing foam.  The 
lower layer was drained from the funnel until the middle layer was found. The middle 
layer (containing the microbubbles) was collected in a 50 ml centrifuge tube. It was later 
diluted using membrane filtered PBS for acoustic testing of microbubbles 
 
Figure 3.2:  Paclitaxel loaded standard micro and nanobubbles in separation funnel after the second wash 
with 50 ml of cold PBS.  Funnel A contains microbubbles and Funnel B contains nanobubbles.  
3.2.2 Effect of varying sodium chloride and surfactant  
The main goal of thesis was to increase the drug encapsulation efficiency in nanobubbles 
and get higher nanobubble population. The concentration of total sodium chloride and 
TPGS were varied to achieve high nanobubble population with higher stability. The first 
B 
A 
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part of the study involves variation in the amounts of total sodium chloride to find which 
salt concentration gave the maximum enhancement.  In the second part of the study, 
molar ratio of Span 60: TPGS was varied in the SE61 mixture to find which ratio gave 
the highest nanobubble population. Also, effects of sodium chloride and TPGS ratios 
were studied for microbubbles echogenecity and stability.  
3.3 Direct Drug loading Method 
For direct drug loading, 100 µg/ml of paclitaxel was used which corresponds to 5 mg of 
paclitaxel in 50 ml of surfactant mixture. The detailed SOP for loading of paclitaxel in 
the drug is mentioned in Appendix B.7. In brief, paclitaxel was weighed out and added in 
the stirred autoclaved surfactant mixture. The mixture was heated at about 100◦ C with 
constant stirring for 30 min on a magnetic stirrer. The solution was cooled to room 
temperature by constant stirring for 35-45 min. The mixture was then sonicated as usual 
and separated using 4oC PBS (pH 7.4). 
3.4 Characterization of bubbles and drug loaded bubble 
The Standard SE61, varied SE61 (varying total sodium chloride and TPGS ratios) and 
drug loaded bubbles were tested for in-vitro acoustic properties using echogenecity 
testing (dose response) and stability. Further characterization of the bubbles and drug 
loaded bubbles were done using size analysis, zeta potential measurement and turbidity 
measurement at 610 nm. Three independent trials were conducted for each condition 
showing repeatability and accuracy in the results. 
3.4.1 Dose and Time Response 
Initial set up of the function generator was done with pulse repetition frequency being 
adjusted to 100 Hz, energy to 1 and damping to 3. A 5072 pulser-receiver (Waltham, 
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MA) was used to generate acoustic pressure with pulse repetition (PRF) frequency of 100 
Hz. A Lecroy 9350 A 500 Hz Oscilloscope was used and set to 1µs and 100mV shown in 
figure 3.3. 
 
Figure 3.3: Lecroy 500MHz Oscilloscope used during acoustic testing of bubbles. 5MHz transducer was 
used with delay adjusted to 62µs in the oscilloscope. The gain is adjusted to 40dB for acoustic testing. 
 
A custom built vessel has acoustic window (1.5 inches by 1.5 inches) was used for 
acoustic testing of micro and nanobubbles. Membrane filtered PBS (50 ml) with pH 7.4 
at 37◦C was transferred into the custom vessel. This custom vessel was placed in a 
rectangular tank which is temperature controlled (37oC) and half filled with DI water as 
shown in figure 3.4. A stir bar was added to the custom vessel and the stirrer is adjusted 
to level 3. A single Panametric (Waltham, MA) 5 MHz transducer (-6dB bandwidth of 
91% and 12.7 mm in diameter) was used with delay being adjusted 62 µs in the 
oscilloscope. Initially the transducer is focused through the transparent window till a 
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signal was seen at 20dB gain. Later the gain is adjusted to 40dB. Lab VIEW 7.1 
(National Instruments) software was used for analysis.  
 
Figure 3.4 Set up of the ultrasound tank for acoustic testing of the bubbles (A). The tank is filled with DI 
water half way above the 5MHz transducer probe (D). The acoustic window of custom build vessel is 
shown in (B). Membrane filtered PBS (50 ml) is added to custom built sample vessel and fitted at 
appropriate position with stirrer level adjusted to 3 (C).  
 
The baseline acquisition was first made (PBS alone) and then the required dose of the 
SE61 or drug loaded SE61 was added to the sample vessel using a 50-200 µl pipette. 
Cumulative dose response study was performed where amplification is read at 40dB. For 
the response with respect to time, a dose on the rise of dose response curve was used. 
This gave us information about the stability of the bubbles in the ultrasound beam.  Data 
are plotted as dB normalized to the initial values time to account for inter sample 
variations. The half life of the bubbles were calculated from the point on the 
C 
B 
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enhancement vs. time curve where initial normalized enhancement drops to 0.5. The 
stability response for microbubbles was done for 15 min and for nanobubbles stability 
response was for 10 min. 
3.4.2 Size Analysis  
The detailed size analysis procedure of bubble and particles is mentioned in Appendix 
B.4. Briefly, a Zetasizer nano ZS (Malvern Inst., UK) instrument was used for size 
analysis. For size analysis of mixtures prior to sonication, 1000 µl of room temperature 
autoclaved SE61 mixture was transferred into tapered cuvettes.  In the case of 
nanobubbles, 1000µl of the nanobubble suspension was taken and transferred directly 
into the cuvette without dilution. But in case of microbubbles, 200µl of microbubbles is 
transferred to a 10ml volumetric flask where the volume was made up to the mark with 
membrane filtered PBS (pH 7.4). After gentle mixing, 1000µl from the 10ml volumetric 
flask was transferred to the tapered cuvette for size analysis. The measurement was taken 
three times and the cuvette is gently shaken before each run. The z-average diameter in 
nm was noted down each time. 
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Figure 3.5: Photo of the Malvern Zetasizer nano ZS instrument with tapered cuvettes placed in the slot of 
the instrument (A).  
 
3.4.3 Zeta potential of the particles and bubbles 
The magnitude of zeta potential gives information about the charge of the bubbles and the 
tendency to aggregate, which increases as the value tends to zero. The basic idea of 
investigating the zeta potential was to study which concentration of total sodium chloride 
and which Span 60: TPGS molar ratio gave the most stable nanobubbles for drug loading 
and HPLC studies. 
The detailed procedure of zeta potential measurement of bubble and particles is given in 
Appendix B.5. Briefly, a Zetasizer nano ZS (Malvern Inst., UK) instrument was used for 
measuring zeta potential. For zeta potential of particles, 1000µl of room temperature 
autoclaved SE61 mixture was transferred into Zeta sizer Nano series capillary cuvettes 
(Malvern Inst., UK). In case of nanobubbles, 1000µl of the nanobubbles was taken and 
transferred directly in the cuvette without dilution. But in case of microbubbles, 200µl of 
A 
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microbubbles was transferred in 10ml volumetric flask where the volume was made up to 
the mark with 37◦C membrane filtered PBS (pH 7.4). 1000µl from the 10ml volumetric 
flask was transferred in the cuvette for zeta potential of microbubbles. The measurement 
was taken three times and the cuvette is gently shaken before each run .The ZP –average 
in mV is noted down 
3.4.4 Turbidity measurement at 610nm 
One of the objectives of the thesis was to study the effect of varying total salt 
concentration and surfactant TPGS ratios on the nanobubble population. Due to difficulty 
in counting the number of nanobubbles, increase or decrease in the amount of 
nanobubbles produced was compared by means of turbidity measurement (absorbance 
scan) at 610nm [112-114]. The detailed procedure for turbidity measurement is 
mentioned in Appendix B.6. Tecan infinite M 200 (Research Triangle Park, NC) 
instrument was used as shown in figure 3.6. 
 
Figure 3.6: Photo of the Tecan infinite M 200 instrument (A) with 96 corning flat transparent plate reader 
(B) on the top of the instrument 
A 
B 
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Non-sterile Polystyrene, Flat bottom, medium binding costar 96 corning flat transparent 
plate reader ( Corning, NY) was used for turbidity measurement. 10µl of nanobubbles 
and 190 µl of cold PBS pH 7.4 was added in the well of the plate reader and scanned 
from 230 nm to 1000 nm. 
3.4.5 Efficiency of paclitaxel encapsulation by high performance liquid 
chromatography 
The detailed procedure for studying the efficiency of paclitaxel encapsulation is 
described in Appendix B.8. In brief, 2.5 ml of ethyl acetate was added to 2.5 ml of 
paclitaxel loaded bubbles and vortexed for 1 min. Later centrifugation is performed using 
Beckman Coulter AllegraTM 21 centrifuge with relative centrifugal force being adjusted 
to 8528 g for 15 min. After centrifugation, 2 separated layers are formed. The upper layer 
consists of ethyl acetate with paclitaxel in it and the lower layer consists of span 60 and 
TPGS. Ethyl acetate containing paclitaxel (1.5 ml of the upper layer) was pipette out into 
a glass bottle and the remaining lower layer containing span 60 and TPGS was discarded 
out. Ethyl acetate in the glass bottle was evaporated and then 1.5 ml of Acetonitrile was 
added to glass bottle and sealed with parafilm. The glass bottle is kept for shaking for 24 
hours. The extracted paclitaxel in acetonitrile in glass bottle was filtered using thermo 
scientific Nalgene 0.2 µm syringe filter. Regular 3ml sterile luer tip syringe was used for 
transferring the paclitaxel extracted into 1 ml vials. Waters 1525 Binary HPLC Pump 
(reverse-phase) was used to study the efficiency of encapsulation [115] shown in figure 
3.7. The HPLC column used was Inertsil ODS column (GL Science, Tokyo, Japan) with 
5 µm particle size and dimensions of 250 mm by 4.6 mm. The mobile phase used was 
100 % acetonitrile HPLC grade. The flow rate used was 1ml/min [116, 117]. 50µl of the 
sample is injected and run for 30 min. UV detection at 227 nm is used [116, 117]. From 
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the salt and surfactant studies, concentration which gave highest population of 
nanobubbles and microbubbles were chosen. Paclitaxel was loaded in the newly 
formulated bubbles and the standard micro and nanobubbles. HPLC was used to study the 
efficiency of paclitaxel encapsulation in newly formulated and standard micro and 
nanobubbles. The calibration curve of paclitaxel for concentrations 0.0537 to 268.5 
µg/ml (prepared by our lab member Boriphat Methachan) with R2= 0.99 was used for 
studying the drug encapsulation efficiency. The set up of HPLC is shown in figure 3.7. 
 
 
Figure 3.7: High Performance Liquid Chromatography (HPLC) used for studying Paclitaxel encapsulation 
efficiency 
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3.4.6 Light microscopy 
Olympus 1X71 light microscope was used for taking the pictures of SE61 microbubbles 
and nanobubbles with and without paclitaxel being loaded. SPOT advanced software was 
used for taking the images.  
3.5 Statistical Analysis 
All statistical analysis was done using Microsoft excel 2007. t- Tests, one-way and two- 
way ANOVA were performed for the data sets to give information about the statistical 
significance of the hypothesis of the experiments. The alpha value used to judge 
statistical significance is 0.05.  
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CHAPTER 4: RESULTS AND DISCUSSION 
 
The new agent SE61 was prepared by replacing Tween 80 by TPGS in the standard 
protocol for preparing ST68. However, the protocol has been changed from the original 
method for ST68 and despite the successful generation of microbubbles, it was not 
known what steps affect the yield, properties of SE61, and on generation of the nano 
population. In the original agent ST68, an initial grinding step was introduced to 
intimately mix the fatty solid span and the viscous Tween 80 before sonication. However, 
since the initial studies with ST68 the protocol has been changed to include a heating step 
and autoclaving, and the salt/grinding step was discontinued. However, it was observed 
that having no added sodium chloride in the SE61 surfactant mixture appeared to produce 
fewer nanobubbles. Although the grinding step was discontinued, the same amount of salt 
was added to the PBS in the solution to be autoclaved, resulting in a total sodium chloride 
concentration of 650 mM in standard SE61 surfactant mixture.  
4.1 Properties of standard SE61 microbubbles   
In this section, the dose response, stability, size and zeta potential of microbubbles are 
studied for standard SE61 in detail.  
4.1.1 Acoustic characterization of standard SE61 microbubbles 
The acoustic characterization of microbubbles is performed as mentioned in Appendix 
B.2 and B.3. First the baseline acquisition was made with PBS alone and then the 
required dose of microbubbles (prepared with 650 mM total sodium chloride 
concentration and 1: 0.25 molar ratio of span 60: TPGS as in the SOP) was dispensed 
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into the custom built vessel kept in the ultrasound tank. A cumulative dose response 
study was performed. For the response with respect to time, a dose on the rise of the dose 
response curve was used. The stability response for microbubbles was performed for 15 
minutes. 
4.1.1.1 Dose response of standard SE61 microbubbles 
In figure 4.1, dose response of standard SE61 microbubbles is shown. A small degree of 
shadowing started to occur at a dose of 60 µl/L with maximum contrast enhancement of 
25.72 ± 0.855 dB.  
 
Figure 4.1: Dose response of standard SE61 microbubbles, N=3 independent observations and error bars 
representing standard error about the mean. 
 
4.1.1.2 Stability response of standard SE61 microbubbles 
In the figure 4.2, half life of standard SE61 microbubbles is shown. The dose chosen for 
stability response was 12 µl/L corresponding to 30 µl of microbubbles added to the 
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custom built vessel. This dose was chosen because it was found to be in the linear range 
of dose response curve for both paclitaxel loaded and non-paclitaxel loaded 
microbubbles. The half lives of the bubbles were calculated from the point on the 
enhancement vs. time curve where initial normalized enhancement drops to 0.5 as shown 
in figure 4.2. The half life of standard SE61 microbubbles is 7.75 ± 1.97 minutes.   
 
Figure 4.2: Half life of standard SE61 microbubbles, N=3 independent observations and standard error bars 
representing standard error about the mean.  
 
4.1.2 Size of standard SE61 microbubbles 
The average diameter of microbubbles was 2203 ± 95 nm (standard error of mean) for 
standard SE61 microbubbles.  
4.1.3 Zeta potential of standard SE61 microbubbles 
The zeta potential of standard SE61 microbubbles was -8.5 ± 0.46 mV.   
4.2 Effect of added sodium chloride on SE61 microbubbles  
The additional sodium chloride concentration in the entire SE61 mixture was varied to 
study its effect on microbubble enhancement and stability to form a basis for comparison 
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with the separated nano component. The sodium chloride concentration in the PBS buffer 
was kept constant (137 mM) and additional sodium chloride was added to the 50 ml of 
SE61 surfactant mixture. The effect of additional sodium chloride in the surfactant 
mixture on microbubble echogenecity, stability, size, zeta analysis is studied in this 
section.  
4.2.1 Acoustic characterization of varying total sodium chloride microbubbles  
The acoustic characterization of microbubbles is performed as mentioned in Appendix 
B.2 and B.3. A cumulative dose response study was performed. For the response with 
respect to time, a dose on the rise of the dose response curve was used. The stability 
response of microbubbles was performed for 15 minutes.  
4.2.1.1 Dose response of total sodium chloride varying microbubbles  
In figure 4.3, dose response of microbubbles are compared at different total (that from the 
PBS and the added salt) sodium chloride concentrations ( p> 0.05) at dose of 40 µl/L, 
implying additional sodium chloride concentration does not have statistically significant 
effect on enhancement of microbubbles. In the trend, 262 mM total sodium chloride 
concentration microbubbles shows slightly higher enhancement compared to other salt 
concentrations. There is no statistically significant difference in the enhancement 
between 262 mM and 650 mM (standard) total sodium chloride concentration 
microbubbles (p> 0.05) at dose of 40 µl/L. In case of 262 mM total sodium chloride 
concentration, the maximum contrast enhancement is 28 ± 1.5 dB at dose of 60 µl/L of 
microbubbles. Shadowing occurred at dose of 60 µl/L with maximum contrast 
enhancement of 25.72 ± 0.855 dB for standard SE61 microbubbles.  
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Figure 4.3: Dose response of microbubbles at different total sodium chloride concentration keeping span 60 
and TPGS constant, p> 0.05 ( one way ANOVA) at dose of 40 µl/L, N=3 independent observations and 
error bars representing standard error about the mean.  
 
4.2.1.2 Stability response of total sodium chloride varying microbubbles  
The dose chosen for stability response was 12 µl/L of microbubbles for non-paclitaxel 
loaded and paclitaxel loaded microbubbles. The half lives of the bubbles were calculated 
from the point on the enhancement vs. time curve where initial normalized enhancement 
drops to 0.5. In figure 4.4, stability of microbubbles at different total sodium chloride 
concentrations are compared (p> 0.05). The additional sodium chloride added to 50 ml of 
SE61 mixture does not statistically significant effect on the half life of microbubbles. 
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There is no statistically significant difference in the half life of microbubbles (p> 0.05) 
between 262 mM and standard (650 mM) microbubbles. The half life of standard (650 
mM) SE61 microbubbles 7.75 ± 1.97 minutes and of 262 mM total sodium chloride is 
8.23 ± 2 minutes.  
 
Figure 4.4: Half life of microbubbles at different total sodium chloride concentrations, p> 0.05, N=3 
independent observations and error bars representing standard error about the mean. 
 
4.2.2 Size of total sodium chloride varying microbubbles  
 
In figure 4.5, size of microbubbles at different total sodium chloride concentrations are 
compared (p> 0.05). The additional sodium chloride added to SE61 surfactant mixture 
does not have statistically significant effect on the size of microbubbles.  
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Figure 4.5: Size of microbubbles at different total sodium chloride concentrations, p> 0.05, N=3 
independent observations and error bars representing standard error about the mean 
  
4.2.3 Zeta potential of total sodium chloride varying microbubbles  
In figure 4.6, zeta potential of microbubbles at different total sodium chloride 
concentrations are compared with p> 0.05. The additional sodium chloride added to 50 
ml of SE61 surfactant mixture does not have statistically significant effect on the zeta 
potential of microbubbles. The zeta potential of the microbubbles with 262 mM total 
sodium chloride concentration is -8.8 ± 0.66 mV. The zeta potential of standard SE61 
microbubbles is -8.5 ± 0.46 mV. The magnitude of zeta potential of 262 mM total sodium 
chloride microbubble is slightly higher than standard (650 mM) microbubbles. However, 
it must of be noted that the presence of sodium chloride could be influencing the results 
by shielding the actual charge.  
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Figure 4.6: Zeta potential of microbubbles at different total sodium chloride concentrations, p> 0.05, N=3 
independent observations and error bars representing standard error about the mean 
 
4.2.4 How are newly formulated microbubbles different from standard SE61 
microbubbles from the salt study:  
In the newly formulated microbubbles, the total sodium chloride concentration chosen is 
262 mM over the standard 650 mM total sodium chloride concentration. In case of 
262mM total sodium chloride concentration, the maximum contrast enhancement is 28 ± 
1.5 dB at dose of 60 µl/L of microbubbles. Shadowing occurred at dose of 60 µl/L with 
maximum contrast enhancement of 25.72 ± 0.855 dB for standard SE61 microbubbles. 
The half life of standard (650mM) SE61 microbubbles 7.75 ± 1.97 minutes which is 
slightly lower than  262 mM total sodium chloride ( 8.23 ± 2 minutes) microbubbles.   
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4.3. Effect of surfactant ratio on microbubbles  
The TPGS concentration was varied in the SE61 surfactant mixture keeping span 60 and 
total sodium chloride concentration same as used in standard SE61 microbubbles.  
4.3.1 Acoustic characterization of microbubbles with different surfactant ratio 
The acoustic characterization of microbubbles is performed as mentioned in Appendix 
B.2 and B.3 
4.3.1.1. Dose response of microbubbles  
In the graph shown in figure 4.7, dose response of standard (1: 0.25) SE61, 1: 0.43 and 1: 
0.67 molar ratio microbubbles are compared with p < 0.05. Shadowing occurred at dose 
of 60 µl/L with maximum contrast enhancement of 25.72 ± 0.855 dB for standard (1: 
0.25) SE61 microbubbles. The maximum contrast enhancement for 1: 0.43 and 1: 0.67 
molar ratio microbubbles are 24.9 ± 1.36 dB ( dose of 60 µl/L) and 20.8 ± 0.36 dB ( dose 
of 80 µl/L) respectively.   
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Figure 4.7: Comparison of dose response of microbubble at different TPGS concentrations, p < 0.05 at dose 
of 200 µl/L (One way ANOVA), N=3 independent observations and error bars representing standard error 
about the mean.  
 
4.3.1.2. Stability response of microbubbles  
In figure 4.8, half life of the microbubbles are compared at different TPGS 
concentrations, using one way ANOVA with p >0.05. There is no statistically significant 
difference in half life of microbubbles having standard (1: 0.25) and 1: 0.43 molar ratio 
of span 60: TPGS. The half life of microbubbles having 1: 0.67 molar ratios is 3.3 ± 0.72 
minutes.  
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Figure 4.8: Half life of the microbubbles at different TPGS concentrations, One way ANOVA: p >0.05, 
N=3 independent observations and error bars representing standard error about the mean. 
 
Increasing the TPGS concentration in SE61 mixture does not have statistically significant 
effect on the half life of the microbubbles. 
4.3.2 Size of microbubbles at different TPGS concentrations. 
In figure 4.9, size of microbubbles is compared at different TPGS concentrations using 
one way ANOVA with p< 0.05. Increasing the TPGS concentration has statistically 
significant effect on the size of microbubbles. The size of 1: 0.67 molar ratio 
microbubbles is significantly smaller with average diameter of 1227 ± 99 nm.  
53 
 
 
Figure 4.9: Comparison of size of microbubbles at different TPGS concentrations, p< 0.05 (One way 
ANOVA), N=3 independent observations and error bars representing standard error about the mean. 
 
4.3.3 Zeta potential of microbubbles  
The zeta potential of microbubbles is compared in Figure 4.10 with p< 0.05.  
 
Figure 4.10: Comparison of zeta potential of microbubbles at different TPGS concentrations, p< 0.05 (One 
way ANOVA), N=3 independent observations and error bars representing standard error about the mean  
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The zeta potential of 1: 0.67 molar ratio nanobubbles is significantly lower with value of 
-6.8 ± 0.19 mV.  
4.3.4. How is newly formulated microbubble different from the standard SE61 
microbubbles 
From the TPGS study, 1: 0.25 molar ratio of span60: TPGS is chosen over concentrations 
Also, 1: 0.43 did not have statistically significant difference when compared with 
standard (1: 0.25) for echogenecity, half life and zeta potential of microbubbles.  
4.4 Paclitaxel encapsulation in microbubbles  
The second aim of the thesis was to investigate the possibility of incorporating a 
hydrophobic drug in to the microbubbles with the possibility of using the agent to deliver 
drug directly to a tumor in the presence of ultrasound. 
4.4.1 Acoustic characterization of paclitaxel loaded microbubbles  
The acoustic characterization of microbubbles is performed as mentioned in Appendix 
B.2 and B.3.  
4.4.1.1 Dose response of paclitaxel loaded microbubbles  
Paclitaxel was loaded into the newly formulated microbubbles (with 262 mM total 
sodium chloride concentration and 1: 0.25 molar ratio of span: TPGS) and standard SE61 
microbubbles in figure 4.11. At maximum dose of 200 µl/L, there is statistically 
significant difference in the contrast enhancement with p< 0.05, with the new formulation 
showing a great extent of shadowing.  
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Figure 4.11: Comparison of dose response of paclitaxel loaded standard SE61; paclitaxel loaded newly 
formulated and standard SE61 microbubbles, p <0.05 at dose of 200 µl/L, N=3 independent observations 
and error bars representing standard error about the mean.  
 
The maximum enhancement of paclitaxel loaded standard SE61 and without drug 
standard SE61 are 24.3 ± 0.77dB and 25.72 ± 0.855 dB respectively at dose of 60 µl/L. 
There is no statistically significant difference in enhancement between paclitaxel loaded 
in standard SE61 and no-drug standard SE61 microbubbles.  
4.4.1.2 Stability response of paclitaxel loaded microbubbles  
The half life of the paclitaxel standard SE61microbubbles and paclitaxel loaded newly 
formulated microbubbles are compared in figure 4.12 with p> 0.05.  
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Figure 4.12: Half life of paclitaxel loaded standard SE61 and paclitaxel loaded newly formulated 
microbubbles, p>0.05, N=3 independent observations and error bars representing standard error about the 
mean.  
When considering stability, we would like the bubbles to break easily and release the 
drug, i.e., to be unstable in the US beam, so in the case of the two agents described here, 
it would appear that there is no distinct advantage stability-wise of using one over the 
other. Also, there is no statistically significant difference in half life of paclitaxel loaded 
and no paclitaxel loaded microbubbles.  
4.4.2. Size of paclitaxel loaded microbubbles  
The different molar ratios of surfactants did not appear to influence the microbubble size, 
as seen in figure 4.13. The size of microbubble is not statistically significantly affected by 
paclitaxel loading.  
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Figure: 4.13: Size of paclitaxel loaded standard SE61 and newly formulated microbubbles, p> 0.05, N=3 
independent observations and error bars representing standard error about the mean. 
 
4.4.3 Zeta potential of paclitaxel loaded microbubbles  
In figure 4.14, zeta potential of paclitaxel loaded standard SE61 and paclitaxel loaded 
newly formulated microbubbles (p> 0.05) are compared. Also the zeta potential of 
paclitaxel loaded standard SE61 and non-paclitaxel loaded SE61 are not statistically 
significant.  
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Figure 4.14: Zeta potential of paclitaxel loaded standard SE61 and newly formulated microbubbles, p> 
0.05, N=3 independent observations and error bars representing standard error about the mean. 
 
4.4.4 Encapsulation efficiency of paclitaxel in the micro bubbles by high 
performance liquid chromatography 
Initial paclitaxel concentration loaded into 50 ml of SE61 surfactant mixture prior to 
sonication was 100 µg/ml. The calibration curve for paclitaxel concentrations from 
0.0537 to 268.5 µg/ml (R2= 0.99) was constructed using HPLC, and used for studying the 
encapsulation efficiency. A comparison in the paclitaxel encapsulation efficiency was 
made between standard (STANDARD-650 mM- 1: 0.25 SE61) microbubble and newly 
formulated (PTX-262mM- 1: 0.25 SE61) microbubble in figure 4.15.  However, there is 
no statistically significant difference in the encapsulation efficiency with p > 0.05.  
% encapsulation efficiency = Amount of paclitaxel encapsulated in the bubbles * 100 
                                                  Total amount of paclitaxel added initially  
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Figure 4.15: Paclitaxel encapsulation in standard SE61 and newly formulated microbubbles, p>0.05, 
N=3 independent observations and error representing standard error about the mean. 
 
One of the aims of the thesis was to investigate parameters that increase the nanobubble 
population. Also, investigating the effects that changing the parameters has on the 
particles in suspension after the autoclaving step may shed light on the mechanism of 
bubble stabilization.  The first step was to document the properties of the nanobubbles 
that were formed by using this current, standard method (SOP) of contrast agent 
preparation. 
  
4.5 Properties of standard SE61 nanobubbles  
 
It was evident from the start that when Tween 80 was replaced by TPGS, the population 
of nano sized bubbles that were generated increased. This was evident from two 
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observations, 1) the very distinct middle band of microbubbles that formed in the mixture 
after sonication with ST68 was not present with SE61, rather a more diffuse band was 
observed, and 2) if the sonicated mixture was separated as usual, but then the lower layer 
that was usually discarded was collected in a second separation funnel, the nanobubbles it 
contained slowly rose to form a layer on top of the liquid. This rather dilute layer was 
collected as is and tested as the nano population.  
The dose response, stability, size analysis, zeta potential and turbidity measurement were 
performed for this sub population of nanobubbles after the micron sized bubbles had 
risen to the middle layer after sonication.  
4.5.1. Acoustic in-vitro testing of standard SE61 nanobubbles  
First the baseline acquisition was made with PBS alone and then the required dose of 
nanobubbles (prepared with 650 mM total sodium chloride concentration and 1: 0.25 
molar ratio of span60: TPGS as in the SOP) was dispensed into the custom built vessel in 
the ultrasound tank as described in the methods section. A cumulative dose response 
study was performed. For the response with respect to time, a dose on the rise of the dose 
response curve was used. The stability response for nanobubbles was performed for 
10min.  
4.5.1.1 Dose response of standard SE61 nanobubbles  
The dose response of standard SE61 nanobubbles is shown in figure 4.16. Shadowing 
occurred at a dose of 400 µl/L of nanobubbles giving maximum enhancement of 22.40 ± 
0.86 dB.  
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Figure 4.16: Dose response of standard SE61 nanobubbles with 650mM total sodium chloride 
concentration (513mM additional sodium chloride added  and 137mM sodium chloride in PBS) and 1: 0.25 
molar ratio of span 60: TPGS, N=3 independent observations and error bars representing standard error 
about the mean. 
 
Compared to the standard microbubble preparations of SE61, the nanoparticles agent 
produces equally strong acoustic reflections (with maximum enhancement of 22.40 ± 
0.86 dB) vs. 25.72 ± 0.855 dB ( standard microbubbles) but are obviously much more 
dilute, since a dose of close to 500 µl is required to reach maximum signal, compare to 60 
µl/L for the micron SE61.   This could also be a function of the small size to the bubbles.   
The scattering cross section σ of a gas bubble (a measure of how strongly it reflects 
ultrasound) is given by the born equation (equation 4.1). 
 
where: σ is scattering cross-section (m2),  r is the radius (m), k is the wave number (2π/λ),  
kr<<1, Ks is the compressibility of the scatterer, K is the compressibility of the 
Equation 4.1 
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suspending medium,  ρs is the density of the scatterer, and ρ is the density of the 
suspending medium. It can be seen that σ  is strongly dependent on radius (r6). 
4.5.1.2 Stability response of standard SE61 nanobubbles 
The stability response of standard SE61 nanobubbles is shown in figure 4.17. The dose 
chosen for stability response was 100 µl/L of nanobubbles. This dose was chosen because 
it was found to be in the linear range of dose response curves for both paclitaxel loaded 
and non-paclitaxel loaded nanobubbles. The half life of the bubbles were calculated from 
the point on the enhancement vs. time curve where initial normalized enhancement drops 
to 0.5 shown in figure 4.17. The average half life of the nanobubble was found to be 0.95 
minutes.  
 
Figure 4.17: Stability response of standard SE61 nanobubbles with 650mM total sodium chloride 
concentration  and 1: 0.25 molar ratio of span 60: TPGS , N=3 independent observations and error bars 
representing standard error about the mean. 
 
The most notable property of the stability of nano bubbles in the ultrasound beam is that 
they are considerably less stable than the micro bubbles with half life of 0.95 minutes as 
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compared to 7.75 ± 1.97 minutes for standard microbubbles. The pressure difference 
between the inside and outside of a spherical bubble of radius r is described by the 
Young-Laplace (Y-L) described in equation 4.2.  
Pvap - Pliq = 2 γ° /r = ∆P  (Equation 4.2) 
Where: Pvap and Pliq are the pressure inside (vapor phase) and outside (liquid phase) of the 
bubble, γ° is the surface tension.  
This is considered to be accurate for larger, micron sized bubbles, where the pressure 
difference is inversely proportional to radius, but appears to be unsatisfactory for nano 
sized bubbles.  This can be seen when considering a free bubble in water (γ' = 0:073 N/m) 
of, for example 10 nm which would have an unsustainable ∆P of 1.5 10 7 Pa (~150 atm) 
[118] . So with surfactant stabilized bubbles, the combined surfactants must be lowering 
the surface tension considerably, but still the effect of radius is still important, leading to 
the difference in stability compared to the micron bubbles.  
 4.5.2 Physical analysis  
This involved size analysis and measurement of zeta potential of nanobubbles. Both 
measurements were performed using Zetasizer nano ZS instrument.  
4.5.2.1 Size of standard SE61 nanobubbles 
The average diameter of standard SE61 nanobubbles ranged from 350-480 nm (figure 
4.18) which can easily pass through the capillaries and enter the target site for imaging.  
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Figure 4.18: Size  of standard SE61 nanobubbles with 650mM total sodium chloride concentration  and 1: 
0.25 molar ratio of span 60: TPGS , N=3 independent observations and error bars representing standard 
error about the mean. 
4.5.2.2 Zeta analysis of nanobubbles 
The zeta potential was measured to give information about the stability of the 
nanobubbles. The magnitude of zeta potential gives information about the charge of the 
bubbles and the tendency to aggregate, which increases as the value tends to zero.  
Higher is the absolute value of zeta potential, higher the surface charge of the bubbles 
and hence higher stability of the bubbles [30]. The zeta potential of standard 
SE61nanobubbles ranged from -7.79 to -6.67 mV (figure 4.19). 
 
Figure 4.19: Zeta potential of standard SE61 nanobubbles, N=3 independent observations and error bars 
representing standard error about the mean. 
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The zeta potential of standard SE61 microbubbles is -8.5 ± 0.46 mV.   
4.5.3 Size of standard SE61 particles prior to sonication 
The particles of span 60 play an important role in stabilization of bubbles. Studying the 
particle size prior to sonication could give us information about the mechanism of bubble 
stabilization. The zeta potential of particles prior to sonication also gives information 
about the stability of particles in the suspension. Both size and zeta potential of particles 
are measured using Zetasizer nano instrument.  
4.5.3.1 Size of particles 
In figure 4.20, average diameter of standard SE61 particles prior to sonication are 
measured. The average diameter of particles ranged from 25-35 nm.  
 
Figure 4.20: Size of standard SE61 particles prior to sonication with 650mM total sodium chloride 
concentration (N=3 independent observations and error bars representing standard error about the mean. 
4.5.3.2 Zeta potential of particles  
The zeta potential of particles prior to sonication gives information about the stability of 
particles that lead to bubble stabilization. The zeta potential for standard SE61 particles 
ranged from -1.7 to -1.8 mV shown in figure 4.21.  
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Figure 4.21: Zeta potential of standard SE61 particles before sonication, N=3 independent observations and 
error bars representing standard error about the mean. 
 
4.6 Effect of added salt on the nanobubble population   
As mention at the start of the results section, addition of sodium chloride to the solution 
to be autoclaved appeared to increase the nano population.  In order to characterize the 
extent of this effect, the additional sodium chloride concentration in the nano samples of 
SE61 mixture was varied to study its effect. The effects of sodium chloride concentration 
in the SE61 mixture on nanobubble echogenecity, stability, size, and zeta analysis and 
nanobubble population are studied in this section.  
4.6.1 Acoustic characterization of nanobubbles prepared at various sodium chloride 
concentrations 
The acoustic characterization of nanobubbles is performed as mentioned in Appendix B.2 
and B.3.  
4.6.1.1 Dose response of nanobubbles  
In figure 4.22, dose response of nanobubbles is studied at different total sodium chloride 
concentrations keeping span 60 and TPGS constant in the preparation steps.  
67 
 
 
Figure 4.22: Dose response of nanobubbles prepared at different total sodium chloride concentrations 
keeping span 60 and TPGS constant, p< 0.05 at dose of 50 µl/L ( one way ANOVA), N=3 independent 
observations and error bars representing standard error about the mean.  
 
The additional sodium chloride added during preparation of SE61 nano has statistically 
significant difference at α= 0.05 (figure 4.22) at dose of 50 µl/L of nanobubbles. A trend 
can be observed with 387 mM total sodium chloride concentration giving maximum 
enhancement of 24 ± 0.16 dB at dose of 300 µl/L of nanobubbles compared to other salt 
concentrations (figure 4.24). Also, 137 mM total sodium chloride concentration (regular 
PBS) nanobubbles with no additional sodium chloride added in SE61 mixture gave lower 
enhancement compared to standard SE61, which is in agreement with the observation 
that additional salt in the initial mixture to be autoclaved appeared to generate fewer nano 
bubbles.  The exact physical reason for this is not immediately apparent, but is appears 
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that a threshold ionic strength has to be reached to stabilize the nano bubbles. Also, the 
nanobubble suspension is very dilute with shadowing occurring around 1200 µl/L 
representing dose of maximum contrast enhancement. An extended version of figure 4.22 
is shown in figure 4.23 
 
Figure 4.23: Extended version of figure 4.7 till dose of 2000 µl/L: Dose response of nanobubbles at 
different total sodium chloride concentrations keeping span 60 and TPGS constant, p< 0.05 at dose of 50 
µl/L ( one way ANOVA), N=3 independent observations and error bars representing standard error about 
the mean.  
In case of microbubbles, the additional sodium chloride added to surfactant mixture did 
not have statistically significant effect on the dose response of microbubbles. Comparing 
387 mM total sodium chloride concentration and standard SE61 with 650 mM sodium 
chloride concentration at dose of 50 µl/L gives p> 0.5. However, 387 mM total sodium 
chloride concentration gave slightly higher maximum enhancement of 24 ± 0.16 dB at 
dose of 300 µl/L than standard (650 mM) SE61. Shadowing occurred at a dose of 400 
µl/L for standard (650 mM) nanobubbles giving maximum enhancement of 22.40 ± 0.86 
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dB. Hence, in the newly formulated SE61, the total sodium chloride concentration chosen 
was 387 mM in 50 ml of surfactant mixture.  
4.6.1.2 Stability response of nanobubbles at different additional sodium chloride 
concentrations 
The dose chosen for stability response was 100 µl/L of nanobubbles for all different total 
sodium chloride concentrations. The half lives of the bubbles were calculated from the 
point on the enhancement vs. time curve where initial normalized enhancement drops to 
0.5 shown in figure 4.24. The data were normalized to allow inter sample comparison. In 
figure 4.24, the half life of nanobubbles at different total sodium chloride concentrations 
keeping span 60 and TPGS concentrations constant are compared. The additional sodium 
chloride concentration has statistically significant effect on half life of nanobubbles with 
p < 0.05 between different salt concentrations (one way ANOVA). In the trend (figure 
4.24), 387 mM total sodium chloride concentration nanobubbles have higher half life 
compared to other salt concentrations. The mean half life of nanobubble with 387 mM 
total sodium chloride concentration is 1.52 minutes. The mean half life of standard SE61 
nanobubbles with 650 mM (SOP) total sodium chloride concentration is 0.95 minutes. 
Statistically significant difference in half life is observed with (p< 0.05) between 
nanobubbles with 387 mM and standard 650 mM total sodium chloride concentrations. In 
the newly formulated nanobubbles, 387 mM total sodium chloride concentration is 
chosen over standard 650 mM total sodium concentrations because nanobubbles are more 
stable with higher half life than standard SE61 nanobubbles.  
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Figure 4.24: Half life of nanobubbles at different total sodium chloride concentrations keeping span 60 and 
TPGS constant in the SE61 surfactant mixture, p< 0.05 (one way ANOVA), N=3 independent observations 
and error bars representing standard error about the mean. 
 
4.6.2 Physical characterization of nanobubbles 
The effect of adding sodium chloride on size and zeta potential of nanobubbles was 
studied in this section. Size and zeta potential of nanobubbles were studied using 
Zetasizer nano ZS instrument.  
4.6.2.1 Size of the nanobubbles  
The size of all nanobubbles at different total sodium chloride concentrations are in range 
of 350-550 nm ideal as ultrasound contrast agent and tumor imaging as they can easily 
pass through the capillaries. In figure 4.25, a comparison is made of size of nanobubbles 
at different total sodium chloride concentrations keeping span 60 and TPGS constant in 
SE61 surfactant mixture. The additional sodium chloride added to the SE61 mixture has 
statistically significant effect on the size of nanobubbles with p< 0.05.  
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Figure 4.25: Size of  SE61 nanobubbles at different total sodium chloride concentrations keeping span 60 
and TPGS constant, p< 0.05 (One way ANOVA), N=3 independent observations and error bars 
representing standard error about the mean.  
 
The 137 mM total sodium chloride concentration nanobubbles with no additional sodium 
chloride are smaller compared to other salt concentrations in the trend (figure 4.25). 
There is no statistically significant difference in size of nanobubbles between 387 mM 
and standard 650 mM total sodium chloride concentrations with p> 0.05.  
4.6.2.2 Zeta potential of nanobubbles  
The zeta potential of nanobubbles at different total sodium chloride concentrations is 
shown in figure 4.28 (p> 0.05). In the trend 387 mM total sodium chloride concentration 
shows slightly higher magnitude of average zeta potential compared to other salt 
concentrations. Since zeta potential gives information about the stability of bubbles, 
387mM total sodium chloride nanobubbles are slightly more stable compared to other salt 
concentrations shown in figure 4.26. 
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Figure 4.26: Zeta potential of SE61 nanobubbles at different total sodium chloride concentrations keeping 
span 60 and TPGS constant, p > 0.05 (one way ANOVA), N=3 independent observations and error bars 
representing standard error about the mean.  
 
There is no statistically significant difference in the zeta potential of nanobubbles at 387 
mM and 650 mM total sodium chloride concentrations with p> 0.05. The zeta potential of 
387 mM total sodium chloride nanobubbles is -7.55± 0.37 mV and for standard (650 
mM) SE61 nanobubbles is -7.1± 0.3 mV. Since the higher magnitude of zeta potential 
means higher stability of bubbles, 387 mM total sodium chloride nanobubbles are slightly 
more stable than standard (650 mM) SE61 nanobubbles. 
4.6.3. Nanobubble population measured by turbidity  
 
Turbidity measurement of the nanobubble suspensions were done to give a measure of 
comparative magnitudes of the nanobubble populations. The wavelength chosen was 610 
nm as the standard value for all our measurements. In figure 4.27, turbidity at 610 nm 
was compared for nanobubbles at different total sodium chloride concentrations keeping 
span 60 and TPGS constant in SE61 mixture (p< 0.05). This implies the additional 
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sodium chloride has significant effect on the nanobubble population. In the trend, 387 
mM total sodium chloride concentration gives higher nanobubble population compared to 
other salt concentrations. This is in agreement with the observations that these conditions 
gave the highest echogenecity.  Also, 137 mM sodium chloride concentration with no 
additional salt added in SE61 mixture yields lower nanobubble population with lower 
turbidity value at 610 nm (figure 4.27) There is statistically significant difference in 
turbidity at 610 nm ( p< 0.05) between 387 mM and standard 650 mM total sodium 
chloride nanobubbles. In the newly formulated nanobubbles, 387 mM is the total sodium 
chloride concentration chosen as the turbidity values are statistically significantly 
different from standard 650 mM total sodium chloride concentration. 
 
Figure 4.27: Turbidity measurement of nanobubbles at different total sodium chloride concentrations 
keeping span 60 and TPGS constant, p< 0.05 ( one way ANOVA), N=3 independent observations and error 
bars representing standard error about the mean.  
 
4.6.4. Size of particles after autoclave  
In figure 4.28, size of the particles prior to sonication at different total sodium chloride 
concentrations (p> 0.05) are compared. A trend can be observed with 137 mM sodium 
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chloride with no additional sodium chloride added in 50 ml of SE61 mixture have particle 
size slightly higher compared to other salt concentrations. And 887 mM total sodium 
chloride SE61 particles having lowest particle size in the trend shown in figure 4.28.  
However there is no statistical difference. 
 
 
Figure 4.28: Comparison of size of particles prior to sonication at different total sodium chloride 
concentrations in SE61 mixture, p> 0.05 (One way ANOVA), N=3 independent observations and error bars 
representing standard error about the mean.  
 
4.6.5 Zeta potential of particles prior to sonication 
Zeta potential of particles prior to sonication is done to study the stability of particles. In 
figure 4.29, zeta potential of particles at different sodium chloride concentrations are 
compared (p < 0.05).  In the trend shown below, 387 mM total sodium chloride particles 
has higher magnitude of average zeta potential compared to other salt concentrations.  
 
75 
 
 
Figure 4.29: Zeta potential of SE61 particles prior to sonication with different total sodium chloride 
concentrations keeping span 60 and TPGS constant, p< 0.05 (one way ANOVA), N=3 independent 
observations and error bars representing standard error about the mean.  
 
There is no statistically significant difference in zeta potential of particles prior to 
sonication between 387 mM and standard 650 mM total sodium chloride concentrations 
(p> 0.05). The zeta potential of particles at 387 mM total sodium chloride concentration 
is -2.58 ± 0.61 mV. The zeta potential of standard 650 mM) a SE61 particle is -1.75 ± 
0.03 mV. The magnitude of zeta potential of 387 mM total sodium chloride nanobubbles 
is slightly higher and hence slightly more stable than standard (650 mM) nanobubbles.  
4.6.6 How the new formulated nanobubbles different from standard nanobubbles  
In the newly formulated nanobubbles, 387mM total sodium chloride concentration is 
chosen over standard 650 mM total sodium concentrations because nanobubbles are more 
stable with higher half life than standard SE61 nanobubbles ( p< 0.05). 387 mM total 
sodium chloride concentration gave slightly higher maximum enhancement of 24 ± 0.16 
dB at dose of 300 µl/L than standard (650 mM) SE61. Shadowing occurred at a dose of 
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400 µl/L for standard (650 mM) nanobubbles giving maximum enhancement of 22.40 ± 
0.86 dB. Also, there is statistically significant difference in turbidity at 610 nm (p< 0.05) 
at these two salt concentrations.   
4.7 Effect of surfactant ratio on the nanobubbles 
The ratio of Span to TPGS used in the contrast agent preparation was based on that used 
in the original ST68 agent.  We now wish to produce an agent with a large population of 
nano bubbles, and so it is important to investigate the effect, if any, that changing the 
span 60: TPGS molar ratio has on this population. 
4.7.1 Acoustic characterization of nanobubbles prepared at different Span 60: 
TPGS ratios 
The acoustic characterization of nanobubbles is performed as mentioned in Appendix B.2 
and B.3.  
4.7.1.1 Dose response of nanobubbles 
The TPGS concentration was varied keeping span 60 and total sodium chloride 
concentration constant in 50 ml of surfactant mixture used in the sonication step. The 
standard SE61 has a molar ratio of 1: 0.25. The TPGS concentration was increased in 
SE61 mixture keeping span 60 constant represented as 1: 0.43 ( 2.808g TPGS) and 1: 
0.67 (3.434g TPGS), and the dose response curves are shown in figure 4.30. A 
comparison was made in dose response of nanobubbles with different TPGS 
concentrations (p > 0.05 at dose of 50 µl/L and maximum dose of 2000 µl/L) in figure 
4.30. There is no statistically significant difference in enhancement between standard (1: 
0.25) and 1: 0.43 ratio nanobubbles with p > 0.05. In the figure 4.30, 1: 0.43 ratio 
nanobubbles (2.208g TPGS) nanobubbles gives slightly higher maximum enhancement 
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(24.2 ± 0.62 dB) than standard (1: 0.25) nanobubbles (22.4 ± 0.86 dB) at dose of 400 
µl/L.  
 
Figure 4.30: Dose response of nanobubbles at different TPGS concentrations keeping span 60 and sodium 
chloride constant, p > 0.05 at dose of  50 µl/L and maximum dose of 2000 µl/L, N=3 independent 
observations and error bars representing standard error about the mean.  
 
This result shows that even if the ratio of surfactant has an effect on the number of nano 
bubbles produced, the acoustic contribution is not distinguishable. 
4.7.1.2 Stability response of nanobubbles 
The half lives of standard (1: 0.25), 1: 0.43, 1: 0.63 molar ratio nanobubbles are 
compared in figure 4.31 with p> 0.05. Also, there is no statistically significant difference 
in the half life of nanobubbles between standard (1: 0.25) and 1: 0.43 molar ratios with 
p> 0.05. The half life of 1: 0.43 molar ratio nanobubbles is 1.25 ± 0.25 min which is 
slightly higher than half life of standard (1: 0.25) nanobubbles (0.9 ± 0.062 minutes).   
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Figure 4.31: Half life of nanobubbles at different TPGS concentrations keeping span 60 and sodium 
chloride constant, p> 0.05, N=3 independent observations and error bars representing standard error about 
the mean.  
 
4.7.2 Physical characterization of nanobubbles 
The effect of adding higher TPGS on size and zeta potential of nanobubbles is studied in 
this section. Size and zeta potential of nanobubbles are studied using Zetasizer nano ZS 
instrument.  
4.7.2.1 Size of the nanobubbles  
The size of nanobubbles between standard (1: 0.25), 1:0.43 and 1:0.67 molar ratio of span 
60: TPGS are compared in figure 4.34 with p< 0.05. The size of nanobubbles at different 
TPGS concentrations range from 350-600 nm which are ideal for tumor imaging. In the 
figure 4.32, 1: 0.43 nanobubbles corresponding to 70 (span 60): 30 (TPGS) molar ratio 
have larger size compared to other TPGS concentrations. Also, there is statistically 
significant difference in size of nanobubbles (p< 0.05) between standard (1: 0.25) and 1: 
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0.43 nanobubbles. Therefore changing the TPGS concentration has statistically 
significant effect on the size of nanobubbles (figure 4.32) 
 
Figure 4.32: Comparison of size of nanobubbles at different TPGS concentrations keeping span 60 and 
sodium chloride constant, p<0.05 (one way ANOVA), N=3 independent observations and error bars 
representing standard error about the mean. 
This is a somewhat unexpected result, since size usually influences echogenecity.  
However, with such small sizes of bubbles (and hence small differences in diameter, in 
the nanometer range), it would appear that the influence is not distinguishable in our 
measurements of acoustic properties (dose and stability response).  However, the result 
does indicate that the molar ratio of the surfactants present during the preparation 
(sonication) stage does influence the packing of surfactant around the gas bubbles, and 
hence the size.  
4.7.2.2 Zeta potential of nanobubbles  
In figure 4.33, zeta potential of standard (1: 0.25), 1:0.43 and 1:0.67 molar ratio 
nanobubbles are compared (p< 0.05). There is no statistically significant difference in 
magnitude of average zeta potential between standard (1: 0.25) and 1: 0.43 molar ratio 
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nanobubbles with p>0.05. The zeta potential of 1: 0.43 nanobubbles is -7.53 ±0.22 mV 
which is slightly higher compared to standard (1: 0.25) nanobubbles (-7.11 ± 0.34mV). 
Higher magnitude of zeta potential means higher stability of bubbles. The nanobubbles 
with 1: 0.43 molar ratio of span: TPGS are slightly more stable than standard (1: 0.25) 
nanobubbles.  
 
Figure 4.33: Comparison of zeta potential of nanobubbles at different TPGS concentrations keeping Span 
60 and sodium chloride constant, p<0.05 (one way ANOVA), N=3 independent observations and error bars 
representing standard error about the mean. 
 
4.7.3 Nanobubble population measured by turbidity  
One way ANOVA was used to study statistical significance between nanobubbles with 
different TPGS concentrations (p< 0.05) shown in figure 4.34. The average turbidity 
measurement for 1: 0.43 nanobubbles at 610 nm is 0.4 and for standard (1: 0.25 ratio) 
SE61 nanobubbles is 0.32.  There is no statistically significant difference in nanobubble 
population (p> 0.05) compared between standard (1: 0.25) and 1: 0.43 nanobubbles. The 
turbidity value at 610 nm for 1: 0.43 molar ratio nanobubbles is 0.39 ± 0.6 and for 
standard (1: 0.25) nanobubbles is 0.32 ± 0.2. The turbidity value for 1: 0.67 molar ratio 
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nanobubbles at 610 nm is 0.22 ± 0.2. There is statistically significant difference in the 
nanobubble population when standard (1: 0.25), 1: 0.43 and 1: 0.67 molar ratio 
nanobubbles are compared with p < 0.05.   
 
Figure 4.34: Turbidity measurement at 610nm for SE61nanobubbles with different TPGS concentrations 
keeping span 60 and sodium chloride constant, p< 0.05 (one way ANOVA), N=3 independent observations 
and error bars representing standard error about the mean.  
 
4.7.4 Size of particles after autoclave  
 
In figure 4.35, sizes of particles prior to sonication are compared for standard (1: 0.25), 1: 
0.43 and 1: 0.67 SE61 mixtures. There is no statistically significant difference in the size 
of particles prior to sonication between standard (1: 0.25 molar ratios), 1: 0.43 and 1: 
0.67 molar ratio SE61 mixtures with p> 0.05. Also, there is no statistically significant 
difference in the size of particles between standard SE61 (1: 0.25 ratio of span: TPGS) 
and 1: 0.43 SE61 with p > 0.05.   
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Figure 4.35: Size of particles prior to sonication at different TPGS concentrations keeping span60 and 
sodium chloride constant, p> 0.05 (one way ANOVA), N=3 independent observations and error bars 
representing standard error about the mean.  
 
4.7.5 Zeta potential of particles prior to sonication 
In figure 4.36, zeta potential of particles prior to sonication is compared for standard (1: 
0.25), 1: 0.43 and 1: 0.67 SE61 mixtures with p< 0.05. There is no statistically significant 
difference in the zeta potential between standard SE61 (1: 0.25 ratio of span: TPGS) and 
1: 0.43 SE61 with p > 0.05. The zeta potential of standard (1: 0.25) particles is -1.75 ± 
0.54 mV and for 1: 0.43 molar ratio particles is -1.98 ± 0.36mV.  
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Figure 4.36: Zeta potential of particles prior to sonication at different TPGS concentrations keeping span60 
and sodium chloride constant, p< 0.05 (one way ANOVA), N=3 independent observations and error bars 
representing standard error about the mean.  
 
4.7.6 How the new formulated nanobubbles from surfactant study different from 
standard nanobubbles  
In the newly formulated nanobubbles, 1: 0.43 ratio of span60: TPGS is used over the 
standard SE61 (1: 0.25 ratio) formulation. There is no statistically significant difference 
in enhancement, turbidity and half life with p> 0.05 between the two concentrations. But 
1: 0.43 ratio nanobubbles (2.208g TPGS) nanobubbles gave slightly higher maximum 
enhancement (24.2 ± 0.62 dB) than standard (1: 0.25) nanobubbles (22.4 ± 0.86 dB) at 
dose of 400 µl/L. The half life of 1: 0.43 molar ratio nanobubbles is 1.25 ± 0.25 min 
which is slightly higher than half life of standard (1: 0.25) nanobubbles (0.9 ± 0.062 
minutes).   
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4.8 New formulated nanobubbles (from salt and surfactant study)  
In the newly formulated nanobubbles, the total sodium chloride concentration chosen was 
387 mM sodium chloride and 1: 0.43 ratio keeping amount of span 60 constant (as 
standard SE61mixture).  
4.9 Paclitaxel encapsulation in the nanobubbles  
Paclitaxel was encapsulated in the nanobubbles and later the efficiency of paclitaxel 
encapsulation was studied by high performance liquid chromatography.  
4.9.1 Acoustic characterization of paclitaxel loaded nanobubbles 
The acoustic characterization of nanobubbles is performed as mentioned in Appendix B.2 
and B.3.  
4.9.1.1 Dose response of paclitaxel loaded nanobubbles 
In figure 4.37, dose response of paclitaxel loaded standard SE61 (with 650 mM total 
sodium chloride and 1: 0.25 ratio of span: TPGS), paclitaxel loaded newly formulated 
SE61 (with 387 mM total sodium chloride and 1: 0.43 ratio of span: TPGS) and standard 
SE61 nanobubbles without paclitaxel are compared. There is statistically significant 
difference at dose of maximum dose of 2000 µl/L when all three conditions are compared 
in figure 4.37. In case of standard SE61 nanobubbles without paclitaxel loaded into it, 
shadowing occurred at a dose of 400 µl/L giving maximum enhancement of 22.40 ± 0.86 
dB. Shadowing occurred at dose of 300 µl/L for both paclitaxel loaded standard SE61 
and paclitaxel loaded newly formulated nanobubbles with maximum contrast 
enhancement as 22.8 ± 0.45 dB and 22.58 ±0.188 dB respectively.  
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Figure 4.37: Dose response of paclitaxel loaded standard SE61nanobubbles (with 650mM total sodium 
chloride concentration and 1: 0.25 ratio of span 60 and TPGS), paclitaxel loaded newly formulated SE61 
nanobubbles (with 387mM total sodium chloride concentration and 1: 0.43 ratio of span 60 and TPGS) and 
standard SE61 nanobubbles without drug, p<0.05 at dose of 2000 µl/L, N=3 independent observations and 
error bars representing standard error about the mean.  
4.9.1.2 Stability response of paclitaxel loaded nanobubbles 
In figure 4.38, paclitaxel loaded standard SE61, paclitaxel loaded newly formulated 
nanobubbles and standard SE61 without paclitaxel are compared with p< 0.05. The 
average half life of standard SE61 nanobubbles is 0.95 min. From the figure 4.38, half 
life of paclitaxel loaded standard SE61 is around 1.4 ± 0.6 minutes. There is statistically 
significant difference in half life of nanobubbles with p< 0.05 between paclitaxel loaded 
standard SE61 and non-paclitaxel loaded standard SE61 nanobubbles. This implies that 
paclitaxel loaded nanobubbles are more stable in ultrasound beam than standard SE61 
nanobubbles. There is statistically significant difference in the half lives of paclitaxel 
loaded standard SE61 and paclitaxel loaded newly formulated nanobubbles with p <0.05.  
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Figure 4.38: Half life of paclitaxel loaded standard SE61nanobubbles, standard nanobubbles and paclitaxel 
loaded newly formulated nanobubbles, p< 0.05, N=3 independent observations and error bars representing 
standard error about the mean.  
 
4.9.2 Physical characterization of paclitaxel loaded nanobubbles 
 The size and zeta potential of paclitaxel loaded nanobubbles are studied in this section. 
Size and zeta potential of paclitaxel loaded nanobubbles are studied using Zetasizer nano 
ZS instrument.  
4.9.2.1 Size of the paclitaxel loaded nanobubbles  
In figure 4.39, size of paclitaxel loaded standard SE61, paclitaxel loaded newly 
formulated nanobubbles and standard SE61 nanobubbles are compared (p > 0.05). There 
is no statistically significant difference is size of paclitaxel loaded standard SE61 and 
paclitaxel loaded newly formulated nanobubbles.  
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Figure 4.39: Size of paclitaxel loaded standard , paclitaxel loaded newly formulated nanobubbles and 
standard SE61 nanobubbles without paclitaxel , p> 0.05, N=3 independent observations and error bars 
representing standard error about the mean. 
 
4.9.2.2 Zeta potential of paclitaxel loaded nanobubbles  
In figure 4.40, zeta potential of paclitaxel loaded standard SE61, paclitaxel loaded newly 
formulated SE61 and standard SE61 nanobubbles are compared with p< 0.05. The zeta 
potential of standard SE61 nanobubbles is -7.11 ± 0.34mV. There is no statistically 
significant difference in the zeta potential between paclitaxel loaded standard SE61 and 
non-paclitaxel loaded standard SE61 with p > 0.05. The zeta potential of paclitaxel 
loaded standard SE61 is – 7.86 ± 0.15 mV. But the magnitude of zeta potential is slightly 
higher than standard SE61 implying the paclitaxel loaded standard SE61 nanobubbles are 
slightly more stable than standard SE61 nanobubbles. The zeta potential of paclitaxel 
loaded a newly formulated nanobubble is -6.57 ± 0.11mV. There is statistically 
significant difference in zeta potential between paclitaxel loaded newly formulated 
nanobubbles and paclitaxel loaded standard SE61 nanobubbles. The newly formulated 
nanobubbles loaded with paclitaxel are less stable because of less negative value of zeta 
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potential compared to paclitaxel loaded standard SE61 nanobubbles, which indicated a 
greater potential to coalesce. 
 
Figure 4.40: Zeta potential of paclitaxel loaded standard SE61nanobubbles, paclitaxel loaded newly 
formulated SE61 nanobubbles and non-paclitaxel loaded standard SE61 nanobubbles , p< 0.05, N=3 
independent observations and error bars representing standard error about the mean 
 
4.9.3 Paclitaxel loaded nanobubble population measured by turbidity 
In figure 4.41, the turbidity of paclitaxel loaded standard SE61 and paclitaxel loaded 
newly formulated nanobubbles are compared with p> 0.05. Comparing turbidity values 
between standard SE61 and paclitaxel loaded standard SE61 gives p> 0.05.  
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Figure 4.41: Turbidity measurement between paclitaxel loaded standard SE61 (with 650mM total sodium 
chloride concentration and 1: 0.25 ratio of span 60:TPGS), paclitaxel loaded newly formulated nanobubbles 
(with 387mM total sodium chloride concentration and 1: 0.43 ratio of span 60: TPGS) and standard SE61 
nanobubbles, p> 0.05, N=3 independent observations and error bars representing standard error about the 
mean. 
Based on turbidity, it would appear that the size of the population of nano bubbles is not 
affected by the formulation.  
4.9.4 Size of paclitaxel added SE61 particles prior to sonication 
The size of paclitaxel loaded SE61 particles are shown in figure 4.42. The size of 
particles in non paclitaxel loaded standard SE61 is 28 ± 2.4 nm. In case of paclitaxel 
loaded SE61 particles 24 ± 4.2 nm. But in case of newly formulated paclitaxel loaded 
particles size of particles is around 14.65 ± 2.4 nm.  
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Figure 4.42: Comparison of size of particles in paclitaxel added standard SE 61 and paclitaxel added newly 
formulated SE61 (with 387mM total sodium chloride concentration and 1: 0.43 ratio of span 60 and TPGS 
in the mixture), p > 0.05, N=3 independent observations and error bars representing standard error about 
the mean.  
 
4.9.5 Zeta potential of paclitaxel added SE61 particles prior to sonication 
The zeta potential of paclitaxel added SE61 particles prior to sonication is shown in 
figure 4.43. There is no statistically significant difference in paclitaxel loaded standard 
SE61 and paclitaxel loaded newly formulated nanobubbles with p> 0.05. The zeta 
potential of standard (650 mM) SE61 particles is -1.75 ± 0.03 mV.  
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Figure 4.43: Zeta potential of particles prior to sonication for paclitaxel added standard SE61 and newly 
formulated SE61, p> 0.05, N=3 independent observations and error bars representing standard error about 
the mean.  
 
4.9.6 Encapsulation efficiency of paclitaxel in the nanobubbles by high performance 
liquid chromatography 
Efficiency of paclitaxel encapsulated in the nanobubbles were calculated. Initial 
paclitaxel concentration loaded into 50 ml of SE61 surfactant mixture was 100 µg/ml. 
The calibration curve by height for paclitaxel concentrations from 0.0537 to 268.5 µg/ml 
(R2= 0.99) was used for studying the encapsulation efficiency. The amount of paclitaxel 
encapsulated in the bubbles is found from the high performance liquid chromatography.  
% encapsulation efficiency = Amount of paclitaxel encapsulated in the bubbles * 100 
                                                  Total amount of paclitaxel added initially  
 
There is no statistically significant difference in the encapsulation efficiency for both the 
nanobubbles with p>0.05 (figure 4.44) 
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Figure 4.44: Paclitaxel encapsulation efficiency compared between standard SE61 and 250mM sodium 
chloride, 2.208g TPGS nanobubbles, p> 0.05, N=3 independent observations and error bars representing 
standard error about the mean.  
 
When compared with microbubbles, paclitaxel loaded in standard SE61 microbubbles 
was 29.4% and in paclitaxel loaded newly formulated microbubbles was 10.98%. In case 
of nanobubbles, formulation change did not affect paclitaxel encapsulation efficiency. 
The encapsulation efficiency of paclitaxel loaded into standard SE61 nanobubbles was 
14.4% and in paclitaxel loaded newly formulated nanobubbles was 13.9%.  
4.10. Light Microscopy  
Light microscope was used to obtain pictures of microbubbles and nanobubbles with and 
without paclitaxel. Spot Advanced software was used for obtaining the pictures.  
 
4.10.1. Microbubbles  
The microbubbles in the size 3 µm are shown in figure 4.45. These are 1: 0.43 SE61 
(non-paclitaxel loaded) microbubbles representing 70: 30 molar ratio of span 60: TPGS. 
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Figure 4.45: Image of 1: 0.43 SE61 microbubbles with 2.208 g TPGS keeping span 60 and sodium chloride 
concentration constant (No paclitaxel and no Ultrasound). Magnification: 40 X 
 
The microbubbles with and without paclitaxel being encapsulated cannot be distinguished 
since SE61 surfactant mixture and paclitaxel are both white in colour. The paclitaxel 
loaded microbubbles with average diameter of 3µm are shown in Figure 4.46. 
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Figure 4.46: Standard (1: 0.25) SE61 microbubbles loaded with paclitaxel (No ultrasound). Magnification 
of 40 X and 1.6 X 
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4.10.2 Nanobubbles  
The bubbles with average diameter of about 1µm are shown in figure 4.47  
 
 
 
Figure 4.47: Image of 1: 0.43 SE61 nanobubbles with 2.208 g TPGS keeping span 60 and sodium chloride 
concentration constant (No paclitaxel and no Ultrasound). Magnification: 40 X and 1.6 X 
 
The nanobubbles are not clearly observed and currently work in going on observing the 
nanobubbles clearly. Also, the nanobubbles with and without paclitaxel cannot be 
identified when figure 4.47 and figure 4.48 are compared. 
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Figure 4.48: Image of paclitaxel loaded newly formulated SE61 nanobubbles (No ultrasound) 
.Magnification 40X and 1.6 X 
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CHAPTER 5: CONCLUSIONS 
 
The acoustic characterization of standard SE61 micro and nanobubbles was studied. The 
average diameter of standard SE61 microbubbles was 2-2.3 µm and provided contrast 
enhancement between 18- 24 dB. Nanobubbles with mean diameter of 350-480 nm were 
separated from the primary mixture and provided contrast enhancement between 18-23 
dB.  
The effect of additional sodium chloride concentration in the SE61 mixture was studied 
for micro and nanobubbles. In case of nanobubbles, the additional sodium chloride had 
statistically significant effect on enhancement at dose of 50 µl/L. However, additional 
sodium chloride did not have statistically significant effect on enhancement of 
microbubbles with p> 0.05. From the salt study, 387 mM total sodium chloride 
concentration gave maximum enhancement of 24 ± 0.16 dB at dose of 300 µl/L of 
nanobubbles. Also, higher nanobubble population was observed at this particular 
concentration.  In case of microbubbles, 262 mM total sodium chloride gave maximum 
contrast enhancement is 28 ± 1.5 dB at dose of 60 µl/L. From the surfactant study, 1: 0.43 
(for nanobubbles) and 1: 0.25 (for microbubbles) molar ratio of span 60: TPGS were 
chosen as ratio in the newly formulated bubbles. 
In the thesis, it has been shown that paclitaxel was incorporated into the SE61 micro and 
nanobubbles, ultrasound contrast agents. The acoustic properties of microbubbles with 
and without paclitaxel were studied and did not reveal statistically significant difference. 
Paclitaxel was loaded into the microbubbles without altering their structure and acoustic 
stability in ultrasound beam. In case of standard SE61 nanobubbles without paclitaxel 
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loaded into it, shadowing occurred at a dose of 400 µl/L giving maximum enhancement 
of 22.40 ± 0.86 dB. Shadowing occurred at dose of 300 µl/L for both paclitaxel loaded 
standard SE61 and paclitaxel loaded newly formulated nanobubbles with maximum 
contrast enhancement as 22.8 ± 0.45 dB and 22.58 ±0.188 dB respectively. Also, the half 
life of paclitaxel loaded standard SE61 nanobubbles was 1.4 ± 0.6 minutes which is 
higher than standard SE61 nanobubbles ( 0.95 min) with p< 0.05.  
High performance liquid chromatography was used to study paclitaxel encapsulation 
efficiency in micro and nanobubbles. In case of nanobubbles, formulation change did not 
affect paclitaxel encapsulation efficiency. The encapsulation efficiency of paclitaxel 
loaded into standard SE61 nanobubbles was 14.4% and in newly formulated nanobubbles 
was 13.9%. When compared with microbubbles, paclitaxel loaded in standard SE61 
microbubbles was 29.4% and in paclitaxel loaded newly formulated microbubbles was 
10.98%.  
The images of paclitaxel loaded and non-paclitaxel loaded bubbles were observed under 
light microscope. Since the colour of SE61 contrast agent and paclitaxel is the same, 
paclitaxel loaded into the hydrophobic region of the bubble was not distinguishable.  
 
 
 
 
 
99 
 
CHAPTER 6: RECOMMENDATIONS 
 
In my thesis work, only one concentration of paclitaxel was used and loaded into micro 
and nanobubbles. Different concentrations of paclitaxel can be loaded into the bubbles to 
see which concentration gives highest encapsulation efficiency in the bubbles.  
The effect of total sodium chloride and TPGS were studied on the population of 
nanobubbles keeping span 60 concentration constant. Since span 60 plays an important 
role in maintaining the structure of bubbles, effect of span 60 concentration on 
nanobubble population can be studied.  
Since paclitaxel and SE61 mixture are both white in colour, the images under light 
microscope were not clear with paclitaxel loaded into the hydrophobic region of the 
bubble. Paclitaxel can be linked to some targeting dye specific to paclitaxel which shows 
the paclitaxel being loaded into the bubbles. Although ultrasound meditated paclitaxel 
delivery enables targeted cancer therapy, increase in specificity towards tumor targeting 
can be done by attaching ligands specific to tumor receptors.   
Also, studies where another anti-cancer drug can be encapsulated along with paclitaxel 
can be done. 
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APPENDIX A: LIST OF NOMENCLATURE USED 
 
Table A.1: Nomenclature of standard SE61 bubbles with total sodium chloride 
concentration and span 60: TPGS molar ratios 
Name Type of bubble  Represented as  
Standard nanobubble with 
650mM sodium chloride 
and 1: 0.25 ratio of span 60 
and TPGS 
Nano STANDARD-650mM- 1: 0.25 SE61n 
Standard microbubble with 
650mM sodium chloride 
and 1: 0.25 ratio of span 60 
and TPGS 
Micro STANDARD-650mM- 1: 0.25 SE61m 
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Table A.2: Amount of additional sodium chloride added and total sodium chloride 
concentration in 50 ml of SE61 surfactant mixture. 
Type of mixture Additional salt 
added in 50 ml of 
surfactant mixture 
Sodium chloride 
in 1L of PBS 
Total sodium chloride 
concentration in 50 ml of 
SE61 mixture 
 (g) (mM) (g) (mM) (mM) 
137mM sodium 
chloride SE61 
0 0 8.01 137 137 
262 mM sodium 
chloride  SE61 
0.366 125 8.01 137 262 
387mM sodium 
chloride SE61 
0.730 250 8.01 137 387 
512mM sodium 
chloride SE61 
1.097 375 8.01 137 512 
Standard (650mM 
sodium chloride) 
SE61 
1.5 513 8.01 137 650 
887mM sodium 
chloride SE61 
2.192 750 8.01 137 887 
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Table A.3: Types of bubbles at different total sodium chloride concentrations 
keeping Span 60 and TPGS constant 
Name  Type of 
the bubble 
Represented as 
137 mM sodium chloride SE61 keeping span 60 
and TPGS constant 
Nano  137mM SE61n 
262 mM sodium chloride  SE61 keeping span 60 
and TPGS constant  
Nano 262 mM SE61n 
387mM sodium chloride SE61keeping span 60 
and TPGS constant 
Nano 387 mM SE61n 
512mM sodium chloride SE61 keeping span 60 
and TPGS constant 
Nano 512 mM SE61n 
Standard (650mM sodium chloride) SE61 
keeping span 60 and TPGS constant  
Nano Standard (650 mM) SE61n 
887mM sodium chloride SE61 keeping span 60 
and TPGS constant 
Nano 887 mM SE61n 
137 mM sodium chloride SE61 keeping span 60 
and TPGS constant 
Micro  137mM SE61m 
262 mM sodium chloride  SE61 keeping span 60 Micro 262 mM SE61m 
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and TPGS constant  
387mM sodium chloride SE61keeping span 60 
and TPGS constant 
Micro 387 mM SE61m 
512mM sodium chloride SE61 keeping span 60 
and TPGS constant 
Micro 512 mM SE61m 
Standard (650mM sodium chloride) SE61 
keeping span 60 and TPGS constant  
Micro Standard(650mM)  SE61m 
887mM sodium chloride SE61 keeping span 60 
and TPGS constant 
Micro 887 mM SE61m 
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Table A.4: Molar ratio of span 60 and TPGS in surfactant study ( changing amount 
of TPGS keeping span 60 and total sodium chloride constant in 50 ml of SE61 
mixture) 
Type of mixture Molar ratio of surfactant 
Span 60 
Molar ratio of surfactant TPGS 
Standard ( 1.288g TPGS) SE61 80 20 
2.208 g TPGS keeping span 60 
and total sodium chloride 
constant  
70 30 
3.434 g TPGS keeping Span60 
and total sodium chloride 
constant  
60 40 
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Table A.5: Nomenclature for TPGS study keeping span 60 and sodium chloride 
constant in surfactant mixture  
Name Type of bubble Represented as  
Standard (1.288g TPGS) 
SE61 
Nano 1 : 0.25 SE61 n 
2.208 g TPGS keeping span 
60 and total sodium 
chloride constant  
Nano 1: 0.43 SE61 n 
3.434g TPGS keeping 
Span60 and total sodium 
chloride constant  
Nano 1: 0.67 SE61n 
Standard ( 1.288g TPGS) 
SE61 
Micro 1: 0.25 SE61m 
2.208 g TPGS keeping span 
60 and sodium chloride 
constant  
Micro 1: 0.43 SE61 m 
3.434 g TPGS keeping 
Span60 and sodium 
chloride constant  
Micro 1: 0.67 SE61m 
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Table A.6: Encapsulation of paclitaxel into newly formulated bubbles  
Name  Type of bubble Represented as 
Paclitaxel loaded nanobubble 
with 387mM sodium chloride 
and 1: 0.43 ratio of span 60 and 
TPGS ( newly formulated)  
Nano PTX-387 mM-1: 0.43 SE61n 
Paclitaxel loaded standard 
nanobubble with 650mM sodium 
chloride and 1: 0.25 ratio of span 
60 and TPGS 
Nano PTX-650 mM- 1: 0.25 SE61n 
Paclitaxel loaded microbubble 
with 262 mM sodium chloride 
and 1: 0.25 ratio of span 60 and 
TPGS ( newly formulated)  
Micro PTX-262mM- 1: 0.25 SE61m 
Paclitaxel loaded standard 
microbubble with 650mM 
sodium chloride and 1: 0.25 ratio 
of span 60 and TPGS 
Micro PTX-650mM- 1: 0.25 SE61m 
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APPENDIX B: STANDARD OPERATING PROCEDURES 
 
B.1.Micro and Nanobubble Preparation 
1. To a clean 300 ml beaker, add calculated amounts of Sodium chloride, TGPS and 
span 60 in 50 ml of PBS. The pH of the PBS (PBS) is adjusted to 7.4 before usage.  
Table B.1: Amount of span 60, TPGS and additional sodium chloride added to 50 
ml of SE61 mixture  
Type of mixture Span 60 (g) TPGS (g) Additional 
sodium chloride 
(g) 
PBS (ml) 
137mM sodium 
chloride SE61 
1.464 1.288 0 50 
262 mM sodium 
chloride  SE61 
1.464 1.288 0.366 50 
387mM sodium 
chloride SE61 
1.464 1.288 0.730 50 
512mM sodium 
chloride SE61 
1.464 1.288 1.097 50 
Standard (650mM 
sodium chloride 
and 1: 0.25 molar 
ratio of span60: 
1.464 1.288 1.5 50 
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TPGS) SE61 
887mM sodium 
chloride SE61 
1.464 1.288 2.192 50 
1: 0.43 SE61 1.464 2.208 1.5 50 
1: 0.67 SE61 1.464 3.434 1.5 50 
 
2. Add a stir bar to the beaker  
3. Cover the beaker with aluminum foil and put 1 inch piece of autoclave tape 
4. Heat the solution with continuous stirring until span 60 and TPGS completely 
dissolve. 
5. Autoclave: Take out the inner part of the autoclave and measure the water level.  The 
water level should be between the 2-2.5 inch mark, if not, adjust the water level 
accordingly.  Turn the heat to maximum so that the water begins heating.  After 
putting in the beakers, put the top back on the autoclave and screw all the knobs in 
place. Wait until seeing the water boils and water vapor comes from the ventilation 
valve. When this happens close the ventilation value and wait until the pressure inside 
reaches the green zone, adjust the heat to 4, and count 35 minutes from there. After 
that close the autoclave switch and let the pressure come down. Also, be sure to wear 
the mitts to avoid causing injury.  Autoclaving is done to reduce the particle size of 
span 60. 
6. Keep the PBS (pH 7.4) in 4◦ C refrigerator  
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7. After this allow the solution to cool by constant stirring the mixture at room 
temperature for 35-45 min. 
8. Keep the separation funnel attached to a clamp in 4◦ C refrigerator  
9. Place the beaker in ice and purge the mixture with octafluoropropane until the 
bubbles cover the solution by placing the tip in the solution. When sonicating, the tip 
supplying the gas will not be in the solution, only the sonication probe will be 
submerged.  
10. For sonication place the pipette tip above the solution and purge the solution with 
octafluoropropane for 3 min at 110 W at flow rate of 50 ml/min using Misonix Inc. 
CL4 tapped horn probe with 0.5” tip, Farmingdale, NY. 
11. Pour the sonicated mixture in the cold separation funnel and add 50 ml of cold PBS.  
12. Because there is no distinct layer after 45 min after the first wash with 50 ml PBS, the 
solution is discarded for 25 ml and then 50-75 ml of the solution is transfer to another 
separation funnel (B). Now we have 2 separation funnels, a previous one that is a 
remaining after the transfer (A) and a new one with 50-75 ml of solution (B). 
13. Add 50 ml of PBS to both the funnels and allow it to separate in the cold fridge for 
45min.  
14. Discard 50ml of the solution from both funnel A and B after 45 min and again add 
50ml of the cold Phosphate buffer in both the funnels.  
15. After 45 min, from funnel A remove the solution until you find the middle layer. 
Collect the layer in the centrifuge tube and place in the cold fridge. The funnel A 
contains the micro-bubbles. 200µl of the microbubbles from the centrifuge tube (from 
funnel A) is transferred into 10 ml volumetric flask which is then made up to mark 
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with 37◦C membrane filtered PBS (pH 7.4). The diluted microbubbles is used for 
dose, time response, size analysis and zeta potential of microbubbles.  
16. For funnel B remove 20 ml of the solution and collect 10 ml in centrifuge tube. Place 
the tube in the cold fridge. The funnel B contains the nanobubbles. The nanobubbles 
from the centrifuge tube can directly be used for dose response, time response, size 
analysis of nanobubbles, zeta potential of the bubbles and turbidity measurement at 
610nm without further dilution. 
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B.2. Enhancement studies (Dose response curve) 
 
1) A 5072 pulser-receiver (Waltham, MA) is used to generate acoustic pressure with a 
pulse repetition frequency of 100Hz. 
2) First the initial set up of the function generator is done. The pulse repetition 
frequency is adjusted to 100Hz, energy to 1 and damping to 3.  
3) Lecroy 9350 A 500 MHz Oscilloscope is used and set to 1µs and 100mV. 
4) Fill the custom vessel for ultrasound testing with 50 ml of 37◦C membrane filtered 1X 
PBS (pH7.4). 
5) A stir-bar is added to the custom vessel to continuously stir the PBS. 
6) This vessel is placed into another cubical tank with 20 gallons of distilled water  
7) The temperature of this cubical tank is maintained at 37◦C  
8) The stirrer is adjusted to level 3 
9) A 5 MHz transducer is used for the acoustic testing with delay being adjusted to 
62µs. 
10) Initially the transducer is focused through the transparent window till a signal is seen 
at 20db gain  
11) On the top of the rectangular tank is Parker positioning system (Edmund Scientific, 
NJ). These adjustable knobs can be used for proper positioning of the transducer and 
for adjusting the signal seen in the oscilloscope. 
12) The gain is adjusted to 40 db 
13) Create a new folder for saving the results in the data folder  
14) Click Ultrasound -- main program-- main ultrasound program--- main 
ultrasound program.vi  
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15) Lab VIEW 7.1 ( National Instruments) software is used for acoustic testing  
16) Click on the run button  
17) Enter the folder path to save the acquired data  
18) In the sample name folder write Baseline and click on Make baseline for the 
acquisition 
19) Click acquire 
20) In the sample name type the dose of the bubble being injected or bubble with the drug 
being injected  
21) Add the required dose of the bubble or bubble with the drug using 50-200µl pipette in 
the custom vessel in the cubical tank  
22) Click acquire  
23) Each time after the previous acquisition replace the PBS in the custom vessel with 
another 50 ml of membrane filtered 37◦C PBS  
24) Repeat with different doses and observe where shadowing effect begins to affect 
enhancement  
25) Export the data to folder created and save them.  
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B.3 Stability Response and half life of the bubble  
 
1) The dose on the rise of dose response curve is used as the dose for time response 
2) Click on capture waveform on set time interval  
3) Interval between Acquisitions is set to 1 min  
4) Number of time points to acquire is set to 11 for nanobubbles and 16 for 
microbubbles.   
5) In the sample name section write the dose being used for time response  
6) Press acquire  
7) Export the data to the folder  
8) Half life in min of the bubble is calculated from the time response data  
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B.4. Size Analysis  
Zetasizer nano ZS (Malvern Institute, UK) was used for size analysis of particles and 
bubbles. Low volume disposable sizing tapered cuvette was used for size testing. 
B.4.1 Size Analysis of particles after autoclave 
1) Transfer 1000µl of autoclaved and later cooled SE61 mixture in the tapered cuvette  
2) Place the cuvette in the slot of the instrument  
3) Choose DTS (Nano) software for size analysis  
4) The measurement SOP is chosen from the dropdown menu  
5) Choose measure -- sample and write specifics of the sample whose size is being 
measured  
6) The measurement is taken three times and z-average diameter in nm is noted down 
B.4.2 Size Analysis of the bubbles  
1) In case of nanobubbles: 1000µl of the nanobubbles is taken and transferred directly in 
the cuvette without dilution.  
2) In case of microbubbles: 200µl of microbubbles is transferred in 10ml volumetric flask 
where the volume is made up to the mark with 37◦C membrane filtered PBS (pH 7.4). 
1000µl from the 10ml volumetric flask is transferred in the tapered cuvette for size 
analysis of microbubbles 
3) The cuvette were placed into the slot of the instrument  
4) Choose DTS (Nano) software for size analysis  
5) The measurement SOP is chosen from the dropdown menu  
6) Choose measure -- sample and write specifics of the sample whose size is being 
measured  
7) The measurement is taken three times and z-average diameter in nm is noted down. 
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B.5 Zeta potential measurement 
Zetasizer nano ZS (Malvern Institute, UK) was used for measuring zeta potential of 
particles and bubbles. Zeta sizer Nano series Disposable capillary cuvettes (Malvern Inst., 
UK) were used for measuring zeta potential 
  
B.5.1 Zeta potential of particles 
1) Transfer 1000µl of autoclaved and later cooled SE61 mixture in the zeta sizer cuvette 
2) Place the cuvette into the slot of the instrument  
3) Choose DTS (Nano) software   
4) The appropriate Zeta measurement SOP is chosen from the dropdown menu  
5) Choose measure -- sample and write specifics of the sample whose zeta potential is 
being measured  
6) The measurement is taken three times and ZP-average (mV) is calculated from each 
run. 
B.5.2 Zeta Potential of the bubbles  
1) In case of nanobubbles: 1000µl of the nanobubbles is taken and transferred directly in 
the cuvette without dilution.  
2) In case of microbubbles: 200µl of microbubbles is transferred in 10ml volumetric flask 
where the volume is made up to the mark with 37◦C membrane filtered PBS (pH 7.4) 
1000µl from the 10ml volumetric flask is transferred in the tapered cuvette for size 
analysis of microbubbles 
3) The cuvette is then placed into the slot of the instrument  
4) Choose DTS (Nano) software   
5) The zeta measurement SOP is chosen from the dropdown menu  
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6) Choose measure -- sample and write specifics of the sample whose zeta potential is 
being measured  
7) The measurement is taken three times and ZP-average (mV) is calculated from each 
run. 
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B.6 Turbidity measurement of nanobubbles  
1) Start the Tecan infinite M 200 machine ( Research Triangle Park, NC)  
2) Click on Tecan i control 1.3 software  
3) Choose Infinite 200 Reader  instrument  
4) Choose 96 corning Flat Transparent plate reader  from the drop down menu 
5) Drag Absorbance scan option to the bottom center, set number of reads as 5 and 
number of steps as 1 
6) Scan from 230nm to 1000nm.  
7) Non- sterile Polystyrene, Flat bottom, medium binding costar 96 corning Flat 
transparent plate reader ( Corning, NY) is used for the turbidity measurement  
8) Put the plate inside with the nanobubbles in concentration (10µl of nanobubbles and 
190 µl of cold PBS ph 7.4)  
9) Click the start button  
10) Absorbance value at 610nm is used to study the nanobubble population. 
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B.7 Loading of Paclitaxel into the bubbles  
1) To a clean 300 ml beaker, add calculated amounts of Sodium chloride, TGPS and 
Span 60 in 50 ml of PBS. The pH of the PBS  is adjusted to 7.4 before usage.  
2) Add a stir bar to the beaker  
3) Cover the beaker with aluminum foil and put 1 inch piece of autoclave tape 
4) Heat the solution with continuous stirring until Span 60 and TPGS dissolves 
completely. 
5) Autoclave: Take out the inner part of the autoclave and measure the water level.  
The water level should be between the 2-2.5 inch mark, if not, adjust the water level 
accordingly.  Turn the heat to maximum so that the water begins heating.  After putting 
in the beakers, put the top back on the autoclave and screw all the knobs in place. Wait 
until seeing the water boils and water vapor comes from the ventilation valve. When this 
happens close the ventilation value and wait until the pressure inside reaches the green 
zone, adjust the heat to 4, and count 35 minutes from there. After that close the 
autoclave switch and let the pressure come down. Also, be sure to wear the mitts to 
avoid causing injury.  Autoclaving is done to reduce the particle size of Span 60. 
6) Keep the PBS (pH 7.4) in 4◦  
7) After this allow the solution to cool by constant stirring the mixture at room 
temperature for 35-45 min. 
8) Add  100 µg/ml of Paclitaxel to the stirred mixture which corresponds to 5mg of 
the drug in the 50 ml autoclaved SE61 surfactant mixture. Heat/ stir the mixture and care 
should be taken that the solution does not boil. The solution is kept aside for some time 
and later cooled to room temperature for 30-45 min while constant stirring .  
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9) Keep the separation funnel attached to a clamp in 4◦ C refrigerator  
10) Place the beaker in ice and purge the mixture with Octafluoropropane until the 
bubbles cover the solution by placing the tip in the solution. When sonicating, the tip 
supplying the gas will not be in the solution, only the sonication probe will be 
submerged.  
11) For sonication place the pipette tip above the solution and purge the solution with 
Octafluoropropane for 3 min at 110 W at flow rate of 50ml/min using Misonix Inc. CL4 
tapped horn probe with 0.5” tip, Farmingdale, NY. 
12) Pour the sonicated mixture in the cold separation funnel and add 50 ml of cold 
PBS.  
13) Because there is no distinct layer after 45min after the first wash with 50 ml PBS, 
the solution is discarded for 25 ml and then 50-75 ml of the solution is transfer to 
another separation funnel (B). Now we have 2 separation funnels, a previous one that is 
a remaining after the transfer (A) and a new one with 50-75 ml of solution (B). 
14) Add 50 ml of PBS to both the funnels and allow it to separate in the cold fridge 
for 45min.  
15) Discard 50ml of the solution from both funnel A and B after 45 min and again add 
50ml of the cold Phosphate buffer in both the funnels.  
16) After 45 min, from funnel A remove the solution until you find the middle layer. 
Collect the layer in the centrifuge tube and place in the cold fridge. The funnel A 
contains the micro-bubbles. 
17) For funnel B remove 20 ml of the solution and collect 10 ml in centrifuge tube. Place 
the tube in the cold fridge. The funnel B contains the nanobubbles. 
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B.8 Efficiency of Paclitaxel Encapsulation in the bubble by High Performance liquid 
chromatography 
 
1) Add 2.5 ml ethyl acetate to Paclitaxel loaded bubbles  
2) Vortex shaking for 1 min  
3) Centrifuge at 9000rpm for 15 min  
4) Pipette 1.5ml of ethyl acetate (top layer) to glass bottle and evaporate  
5) Add 1.5ml Acetonitrile and then close and seal then shake for 24 hours  
6)  A reverse phase Inertsil ODS column (250mm x 4.6 mm, 5µm particle size, GL 
Science) is used.  
7)  The mobile phase used was 100% Acetonitrile HPLC Grade at flow rate of 1 ml/min.  
8)  Inject sample 50µl and run for 30 min  
9) The column effluent was detected at 227 nm.  
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APPENDIX C: THEORY BEHIND THE STRUCTURE OF THE BUBBLES  
 
The air-water interface is an excellent reflector of ultrasound beam [13]. In our micro and 
nanobubbles perfluorocarbon (gas core) is used which strongly reflects the ultrasound 
beam thus helping in contrast enhancement during imaging. In the old model, 
microbubble is gas-filled micelle formed by surfactant molecules being arranged with the 
hydrophobic tail groups arranged to face the relatively hydrophobic gas bubble and 
hydrophilic head groups facing the aqueous solution [13].  
 
 
Figure C.1  : Old model of microbubble showing the arrangement of Span 60 and Tween 80 in microbubble 
[13]  
The large polar head groups of Tween put forth mutual repulsive forces and  span 60 
molecules sandwiched between the Tween molecules  to moderate the head group 
repulsion [13] as shown in the figure.  
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Unpublished results in our laboratory explain the structure and stability of microbubble 
with another theory.  Pickering emulsions and foams consist of bubbles which are 
stabilized by small solid particles attached to surface [119-122]. In our case the solid 
particles are of span 60 and TPGS is attached to the surface of span particles.  
 
Figure C.2: Solid span 60 attached at the surface of the bubble would stabilize the bubbles [123] 
 
Figure C.3: At the gas-liquid interface span 60 are attached on the bubble surface imparting stability [123] 
 
123 
 
 
LIST OF REFERENCES 
 
1. Frinking, P.J.A., et al., Ultrasound contrast imaging: current and new potential 
methods. Ultrasound Med Biol, 2000. 26(6): p. 965-975. 
 
 
2. Husseini, G.A. and W.G. Pitt, The Use of Ultrasound and Micelles in Cancer 
Treatment. J Nanosci and Nanotechnol, 2008. 8(5): p. 2205-2215. 
 
 
3. Liu, Y., H. Miyoshi, and M. Nakamura, Encapsulated ultrasound microbubbles: 
Therapeutic application in drug/gene delivery. J Control Release, 2006. 114(1): p. 
89-99. 
 
 
4. Husseini, G.A. and W.G. Pitt, Ultrasonic-activated micellar drug delivery for 
cancer treatment. J Pharm Sci, 2009. 98(3): p. 795-811. 
 
 
5. Wheatley, M.A. and S. Singhal, Structural studies on stabilized microbubbles: 
development of a novel contrast agent for diagnostic ultrasound. Reactive 
Polymers, 1995. 25(2-3): p. 157-166. 
 
 
6. Case, T.D., ULTRASOUND PHYSICS AND INSTRUMENTATION. Surg Clin  N 
Am, 1998. 78(2): p. 197-217. 
 
 
7. Obrienjr, W., Ultrasound–biophysics mechanisms☆. Prog Biophys Mol Biol, 
2007. 93(1-3): p. 212-255. 
 
 
8. Newman, P.G. and G.S. Rozycki, THE HISTORY OF ULTRASOUND. Surg Clin 
N Am, 1998. 78(2): p. 179-195. 
 
 
9. Beach, K.W., 1975-2000: A quarter century of ultrasound technology. Ultrasound 
Med Biol, 1992. 18(4): p. 377-388. 
 
 
 
124 
 
 
 
10. Humphrey, V., Ultrasound and matter—Physical interactions. Prog Biophys  Mol 
Biol, 2007. 93(1-3): p. 195-211. 
 
 
11. Wheatley, M.A., et al., Surfactant-stabilized contrast agent on the nanoscale for 
diagnostic ultrasound imaging. Ultrasound  Med Biol, 2006. 32(1): p. 83-93. 
 
 
12. Ophir, J. and K.J. Parker, Contrast agents in diagnostic ultrasound. Ultrasound  
Med Biol, 1989. 15(4): p. 319-333. 
 
 
13. Singhal, S., C.C. Moser, and M.A. Wheatley, Surfactant-stabilized microbubbles 
as ultrasound contrast agents: stability study of Span 60 and Tween 80 mixtures 
using a Langmuir trough. Langmuir, 1993. 9(9): p. 2426-2429. 
 
 
14. Forsberg, F., et al. Comparison of air and perfluorocarbon filled microbubbles for 
ultrasound contrast studies. in Ultrasonics Symposium, 1996. Proceedings., 1996 
IEEE. 1996. 
 
 
15. Basude, R. and M.A. Wheatley, Generation of ultraharmonics in surfactant based 
ultrasound contrast agents: use and advantages. Ultrasonics, 2001. 39(6): p. 437-
444. 
 
 
16. Kaufmann, B.A. and J.R. Lindner, Molecular imaging with targeted contrast 
ultrasound. Curr Opin Biotechnol, 2007. 18(1): p. 11-16. 
 
 
17. Dhanikula, A.B. and R. Panchagnula, Localized paclitaxel delivery. Int J Pharm, 
1999. 183(2): p. 85-100. 
 
 
18. Klibanov, A.L., Microbubble Contrast Agents: Targeted Ultrasound Imaging and 
Ultrasound-Assisted Drug-Delivery Applications. Invest Radiol, 2006. 41(3): p. 
354-362 10.1097/01.rli.0000199292.88189.0f. 
 
 
19. Porter, T.R., et al., Targeted vascular delivery of antisense molecules using 
intravenous microbubbles. Cardiovasc Revasc Med. 7(1): p. 25-33. 
 
 
125 
 
20. Miller, M.W., D.L. Miller, and A.A. Brayman, A review of in vitro bioeffects of 
inertial ultrasonic cavitation from a mechanistic perspective. Ultrasound  Med 
Biol, 1996. 22(9): p. 1131-1154. 
 
 
21. Liu, Y., H. Yang, and A. Sakanishi, Ultrasound: Mechanical gene transfer into 
plant cells by sonoporation. Biotech Adv. 24(1): p. 1-16. 
 
 
22. Umemura, S., et al., Recent advances in sonodynamic approach to cancer 
therapy. Ultrason Sonochem, 1996. 3(3): p. S187-S191. 
 
 
23. Frenkel, V., Ultrasound mediated delivery of drugs and genes to solid tumors. 
Adv Drug Deliv Rev, 2008. 60(10): p. 1193-1208. 
 
 
24. Unger, E.C., et al., Therapeutic applications of microbubbles. Eur J Radiol, 2002. 
42(2): p. 160-168. 
 
 
25. Smith, N.B., et al., Ultrasound-mediated transdermal transport of insulin in vitro 
through human skin using novel transducer designs. Ultrasound Med Biol, 2003. 
29(2): p. 311-317. 
 
 
26. Wheatley, M.A., B.B. Goldberg, and S. Singhal, SURFACTANT-STABILIZED 
MICROBUBBLE MIXTURES, PROCESS FOR PREPARING AND METHODS 
OF USING THE SAME U.S. Patent, Editor. 1994, Drexel University, 
Philadelphia, Pa: USA. p. 4. 
 
 
27. Wick, A.N. and L. Joseph, Sorbitan Monostearate Metabolism, Lack of 
Deposition upon Chronic Feeding. J Agric Food Chem, 1953. 1(5): p. 398-399. 
 
 
28. Hendy, R.J., et al., Long-term toxicity study of sorbitan monostearate (Span 60) in 
mice. Food  Cosmet Toxicol, 1978. 16(6): p. 527-534. 
 
 
29. Li, P.-Y., et al., Poly(l-lactide)-Vitamin E TPGS Nanoparticles Enhanced the 
Cytotoxicity of Doxorubicin in Drug-Resistant MCF-7 Breast Cancer Cells. 
Biomacromolecules, 2010. 11(10): p. 2576-2582. 
 
 
 
126 
 
 
30. Zhang, Z. and S.-S. Feng, Nanoparticles of poly(lactide)/vitamin E TPGS 
copolymer for cancer chemotherapy: Synthesis, formulation, characterization and 
in vitro drug release. Biomaterials, 2006. 27(2): p. 262-270. 
 
 
31. Mu, L. and S.S. Feng, Vitamin E TPGS used as emulsifier in the solvent 
evaporation/extraction technique for fabrication of polymeric nanospheres for 
controlled release of paclitaxel (Taxol®). J Control Release, 2002. 80(1-3): p. 
129-144. 
 
 
32. Yan, A., et al., Tocopheryl polyethylene glycol succinate as a safe, antioxidant 
surfactant for processing carbon nanotubes and fullerenes. Carbon, 2007. 45(13): 
p. 2463-2470. 
 
 
33. Constantinides, P.P., J. Han, and S.S. Davis, Advances in the use of tocols as drug 
delivery vehicles. Pharm Res, 2006. 23(2): p. 243-55. 
 
 
34. Varma, M.V.S. and R. Panchagnula, Enhanced oral paclitaxel absorption with 
vitamin E-TPGS: Effect on solubility and permeability in vitro, in situ and in vivo. 
Eur J Pharm Sci. 25(4-5): p. 445-453. 
 
 
35. Zhang, Z., S. Huey Lee, and S.-S. Feng, Folate-decorated poly(lactide-co-
glycolide)-vitamin E TPGS nanoparticles for targeted drug delivery. 
Biomaterials, 2007. 28(10): p. 1889-1899. 
 
 
36. Traber, M.G., et al., Efficacy of water-soluble vitamin E in the treatment of 
vitamin E malabsorption in short-bowel syndrome. Vol. 59. 1994. 1270-4. 
 
 
37. Ke, W.-T., et al., Physical characterizations of microemulsion systems using 
tocopheryl polyethylene glycol 1000 succinate (TPGS) as a surfactant for the oral 
delivery of protein drugs. J Control Release, 2005. 102(2): p. 489-507. 
 
 
38. Mu, L., et al., Study on surfactant coating of polymeric nanoparticles for 
controlled delivery of anticancer drug. Colloid  Polym Sci, 2004. 283(1): p. 58-
65. 
 
 
 
127 
 
39. Dintaman, J.M. and J.A. Silverman, Inhibition of P-Glycoprotein by D-α-
Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS). Pharm Res, 1999. 
16(10): p. 1550-1556. 
 
 
40. Bansal, T., et al., Novel formulation approaches for optimising delivery of 
anticancer drugs based on P-glycoprotein modulation. Drug Discovery Today, 
2009. 14(21-22): p. 1067-1074. 
 
 
41. Wempe, M.F., et al., Inhibiting efflux with novel non-ionic surfactants: Rational 
design based on vitamin E TPGS. Int J Pharm, 2009. 370(1-2): p. 93-102. 
 
 
42. Peltier, S., et al., Enhanced Oral Paclitaxel Bioavailability After Administration 
of Paclitaxel-Loaded Lipid Nanocapsules. Pharm Res, 2006. 23(6): p. 1243-1250. 
 
 
43. Rowinsky, E.K. and R.C. Donehower, Paclitaxel (Taxol). New Engl J Med, 1995. 
332(15): p. 1004-1014. 
 
 
44. Nicolaou, K.C., W.-M. Dai, and R.K. Guy, Chemistry and Biology of Taxol. 
Angew  Chem Int Ed  Engl, 1994. 33(1): p. 15-44. 
 
 
45. Panchagnula, R., Pharmaceutical aspects of paclitaxel. Int J Pharm, 1998. 172(1-
2): p. 1-15. 
 
 
46. Sonnichsen, D.S. and M.V. Relling, Clinical pharmacokinetics of paclitaxel. Clin 
pharmacokinet, 1994. 27(4): p. 256-69. 
 
 
47. Burt, H.M., et al., Controlled delivery of taxol from microspheres composed of a 
blend of ethylene-vinyl acetate copolymer and poly (d,l-lactic acid). Cancer Lett, 
1995. 88(1): p. 73-79. 
 
 
48. Dordunoo, S.K., et al., Taxol encapsulation in poly(ɛ -caprolactone) 
microspheres. Cancer Chemother  Pharmacol, 1995. 36(4): p. 279-282. 
 
 
49. Release of taxol from poly(epsilon-caprolactone) pastes: effect of water-soluble 
additives. J Control Release, 1997. 44: p. 87-94. 
 
128 
 
 
50. Winternitz, C.I., et al., Development of a Polymeric Surgical Paste Formulation 
for Taxol. Pharm Res, 1996. 13(3): p. 368-375. 
 
 
51. Trynda-Lemiesz, L., Paclitaxel-HSA interaction. Binding sites on HSA molecule. 
Bioorg Med Chem , 2004. 12(12): p. 3269-3275. 
 
 
52. Wani, M.C., et al., Plant antitumor agents. VI. Isolation and structure of taxol, a 
novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc, 
1971. 93(9): p. 2325-2327. 
 
 
53. Donehower, R.C. and E.K. Rowinsky, An overview of experience with taxol* 
(paclitaxel) in the U.S.A. Cancer Treat Rev, 1993. 19(Supplement 3): p. 63-78. 
 
 
54. Guenard, D., F. Gueritte-Voegelein, and P. Potier, Taxol and taxotere: discovery, 
chemistry, and structure-activity relationships. Acc Chem Res, 1993. 26(4): p. 
160-167. 
 
 
55. Parekh, H. and H. Simpkins, The transport and binding of taxol. General 
Pharmacology: The Vascular System, 1997. 29(2): p. 167-172. 
 
 
56. Band Horwitz, S., Mechanism of action of taxol. Trends Pharmacol Sci, 1992. 13: 
p. 134-136. 
 
 
57. van Zuylen, L., J. Verweij, and A. Sparreboom, Role of Formulation Vehicles in 
Taxane Pharmacology. Investigational New Drugs, 2001. 19(2): p. 125-141. 
 
 
58. Gelderblom, H., et al., Cremophor EL: the drawbacks and advantages of vehicle 
selection for drug formulation. Eur J Cancer, 2001. 37(13): p. 1590-1598. 
 
 
59. Engblom, P., et al., Effects of paclitaxel with or without cremophor EL on cellular 
clonogenic survival and apoptosis. Eur J Cancer, 1999. 35(2): p. 284-288. 
 
 
60. Guchelaar, H.J., et al., Clinical, toxicological and pharmaceutical aspects of the 
antineoplastic drug taxol: A review. Clin Oncol, 1994. 6(1): p. 40-48. 
 
129 
 
 
61. Schiff, P.B. and S.B. Horwitz, Taxol stabilizes microtubules in mouse fibroblast 
cells. Proc Natl Acad  Sci, 1980. 77(3): p. 1561-1565. 
 
 
62. Schiff, P.B., J. Fant, and S.B. Horwitz, Promotion of microtubule assembly in 
vitro by taxol. Nature, 1979. 277(5698): p. 665-667. 
 
 
63. Rao, S., et al., 3'-(p-azidobenzamido)taxol photolabels the N-terminal 31 amino 
acids of beta-tubulin. J Biol Chem, 1994. 269(5): p. 3132-3134. 
 
 
64. Takahashi, M., et al., Sensitivity to paclitaxel is not related to p53-dependent 
apoptosis in ovarian cancer cells. Eur J Cancer, 2000. 36(14): p. 1863-1868. 
 
 
65. Javeed, A., et al., Paclitaxel and immune system. Eur J Pharm Sci, 2009. 38(4): p. 
283-290. 
 
 
66. Spratlin, J. and M.B. Sawyer, Pharmacogenetics of paclitaxel metabolism. Crit 
Rev Oncol Hemat, 2007. 61(3): p. 222-229. 
 
 
67. Rowinsky, E.K., L.A. Cazenave, and R.C. Donehower, Taxol: A Novel 
Investigational Antimicrotubule Agent. J Natl Cancer Inst, 1990. 82(15): p. 1247-
1259. 
 
 
68. Brouwer, E., et al., Measurement of Fraction Unbound Paclitaxel in Human 
Plasma. Drug Metab Dispos, 2000. 28(10): p. 1141-1145. 
 
 
 
69. Wiernik, P.H., et al., Phase I Clinical and Pharmacokinetic Study of Taxol. 
Cancer Res, 1987. 47(9): p. 2486-2493. 
 
 
70. Glantz, M.J., et al., Paclitaxel Disposition in Plasma and Central Nervous 
Systems of Humans and Rats With Brain Tumors. J Natl Cancer Inst, 1995. 
87(14): p. 1077-1081. 
 
 
130 
 
71. Baker, S.D., et al., Role of Body Surface Area in Dosing of Investigational 
Anticancer Agents in Adults, 1991–2001. J Natl Cancer Inst, 2002. 94(24): p. 
1883-1888. 
 
 
72. Monsarrat, B., et al., Modification of Paclitaxel Metabolism in a Cancer Patient 
by Induction of Cytochrome P450 3A4. Drug Metab Dispos, 1998. 26(3): p. 229-
233. 
 
 
73. Monsarrat, B., et al., Hepatic metabolism and biliary excretion of Taxol in rats 
and humans. 1993. 39-46. 
 
 
74. Nielsen, D. and T. Skovsgaard, P-glycoprotein as multidrug transporter: a 
critical review of current multidrug resistant cell lines. Biochimica et Biophysica 
Acta (BBA) - Molecular Basis of Disease, 1992. 1139(3): p. 169-183. 
 
 
75. Gottesman, M.M. and V. Ling, The molecular basis of multidrug resistance in 
cancer: The early years of P-glycoprotein research. FEBS Letters, 2006. 580(4): 
p. 998-1009. 
 
 
76. Callen, D.F., et al., Localization of the human multiple drug resistance gene, 
&lt;i&gt;MDR1&lt;/i&gt;, to 7q21.1. Human Genetics, 1987. 77(2): p. 142-144. 
 
 
77. Chin, J.E., et al., Structure and expression of the human MDR (P-glycoprotein) 
gene family. Mol cell biol, 1989. 9(9): p. 3808-20. 
 
 
78. Hennessy, M. and J.P. Spiers, A primer on the mechanics of P-glycoprotein the 
multidrug transporter. Pharm Res, 2007. 55(1): p. 1-15. 
 
 
79. Fiala, R., et al., P-glycoprotein-mediated multidrug resistance phenotype of 
L1210/VCR cells is associated with decreases of oligo- and/or polysaccharide 
contents. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 
2003. 1639(3): p. 213-224. 
 
 
80. Endicott, J.A. and V. Ling, The Biochemistry of P-Glycoprotein-Mediated 
Multidrug Resistance. Annu Rev Biochem, 1989. 58(1): p. 137-171. 
 
 
131 
 
81. Sorrentino, B.P., Gene therapy to protect haematopoietic cells from cytotoxic 
cancer drugs. Nat Rev Cancer, 2002. 2(6): p. 431-441. 
 
 
82. Yang, T.-F., et al., Shell-crosslinked Pluronic L121 micelles as a drug delivery 
vehicle. Biomaterials, 2007. 28(4): p. 725-734. 
 
 
83. Collnot, E.-M., et al., Mechanism of Inhibition of P-Glycoprotein Mediated Efflux 
by Vitamin E TPGS:  Influence on ATPase Activity and Membrane Fluidity.  Mol 
Pharm, 2007. 4(3): p. 465-474. 
 
 
84. Lake, R.A. and B.W.S. Robinson, Immunotherapy and chemotherapy [mdash] a 
practical partnership. Nat Rev Cancer, 2005. 5(5): p. 397-405. 
 
 
85. Minchinton, A.I. and I.F. Tannock, Drug penetration in solid tumours. Nat Rev 
Cancer, 2006. 6(8): p. 583-592. 
 
 
86. Wang, Y. and F. Yuan, Delivery of Viral Vectors to Tumor Cells: Extracellular 
Transport, Systemic Distribution, and Strategies for Improvement. Ann Biomed 
Eng, 2006. 34(1): p. 114-127. 
 
 
87. McDonald, D.M. and P.L. Choyke, Imaging of angiogenesis: from microscope to 
clinic. Nat Med, 2003. 9(6): p. 713-725. 
 
 
88. Zhanwen, X. and et al., The fabrication of novel nanobubble ultrasound contrast 
agent for potential tumor imaging. Nanotechnology, 2010. 21(14): p. 145607. 
 
 
89. Hobbs, S.K., et al., Regulation of transport pathways in tumor vessels: Role of 
tumor type and microenvironment. Proc Natl Acad Sci, 1998. 95(8): p. 4607-
4612. 
 
 
90. Jain, R.K., Normalization of Tumor Vasculature: An Emerging Concept in 
Antiangiogenic Therapy. Science, 2005. 307(5706): p. 58-62. 
 
 
91. Maeda, H., The enhanced permeability and retention (EPR) effect in tumor 
vasculature: the key role of tumor-selective macromolecular drug targeting. Adv 
Enzyme Regul, 2001. 41(1): p. 189-207. 
132 
 
 
 
92. Maeda, H., G.Y. Bharate, and J. Daruwalla, Polymeric drugs for efficient tumor-
targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm, 2009. 71(3): 
p. 409-419. 
 
 
93. Bisht, S. and A. Maitra, Dextran–doxorubicin/chitosan nanoparticles for solid 
tumor therapy. Wiley Interdisciplinary Reviews: Nanomedicine and 
Nanobiotechnology, 2009. 1(4): p. 415-425. 
 
 
94. Folkman, J., Angiogenesis and apoptosis. Sem Cancer Biol, 2003. 13(2): p. 159-
167. 
 
 
95. Rak, J. and J.L. Yu, Oncogenes and tumor angiogenesis: The question of vascular 
[`]supply' and vascular [`]demand'. Sem Cancer Biol, 2004. 14(2): p. 93-104. 
 
 
96. Bouck, N., V. Stellmach, and S.C. Hsu, How Tumors Become Angiogenic, in 
Advances in Cancer Research, F.V.W. George and K. George, Editors. 1996, 
Academic Press. p. 135-174. 
 
 
97. Hanahan, D. and J. Folkman, Patterns and Emerging Mechanisms of the 
Angiogenic Switch during Tumorigenesis. Cell, 1996. 86(3): p. 353-364. 
 
 
 
98. Rak, J., J. Filmus, and R.S. Kerbel, Reciprocal paracrine interactions between 
tumour cells and endothelial cells: the [`]angiogenesis progression' hypothesis. 
Eur J Cancer, 1996. 32(14): p. 2438-2450. 
 
 
99. Jain, R.K., Normalizing tumor vasculature with anti-angiogenic therapy: A new 
paradigm for combination therapy. Nat Med, 2001. 7(9): p. 987-989. 
 
 
100. van Moorselaar, R.J.A. and E.E. Voest, Angiogenesis in prostate cancer: its role 
in disease progression and possible therapeutic approaches. Mol Cell 
Endocrinol, 2002. 197(1-2): p. 239-250. 
 
 
101. Campbell, S.C., ADVANCES IN ANGIOGENESIS RESEARCH: RELEVANCE TO 
UROLOGICAL ONCOLOGY.  J Urol, 1997. 158(5): p. 1663-1674. 
133 
 
 
 
102. Cvetkovic, D., et al., Increased hypoxia correlates with increased expression of 
the angiogenesis marker vascular endothelial growth factor in human prostate 
cancer. Urology, 2001. 57(4): p. 821-825. 
 
 
103. Huss, W.J., et al., Angiogenesis and Prostate Cancer: Identification of A 
Molecular Progression Switch. Cancer Research, 2001. 61(6): p. 2736-2743. 
 
 
104. Zhong, H., et al., Overexpression of Hypoxia-inducible Factor 1α in Common 
Human Cancers and Their Metastases. Cancer Res, 1999. 59(22): p. 5830-5835. 
 
 
105. Zhong, H., et al., Modulation of Hypoxia-inducible Factor 1α Expression by the 
Epidermal Growth Factor/Phosphatidylinositol 3-Kinase/PTEN/AKT/FRAP 
Pathway in Human Prostate Cancer Cells: Implications for Tumor Angiogenesis 
and Therapeutics. Cancer Res, 2000. 60(6): p. 1541-1545. 
 
 
106. Drevs, J., VEGF and angiogenesis: implications for breast cancer therapy. Eur J 
Cancer Suppl, 2008. 6(6): p. 7-13. 
 
 
 
107. Lee, T.-H., et al., Vascular Endothelial Growth Factor Modulates the 
Transendothelial Migration of MDA-MB-231 Breast Cancer Cells through 
Regulation of Brain Microvascular Endothelial Cell Permeability. J Biol Chem, 
2003. 278(7): p. 5277-5284. 
 
 
108. Symmans, F.W., Breast cancer response to paclitaxel in vivo. Drug Resist 
Update, 2001. 4(5): p. 297-302. 
 
 
109. Milas, L., et al., Kinetics of mitotic arrest and apoptosis in murine mammary and 
ovarian tumors treated with taxol. Cancer Chemother Pharmacol, 1995. 35(4): p. 
297-303. 
 
 
110. Milross, C.G., et al., Relationship of Mitotic Arrest and Apoptosis to Antitumor 
Effect of Paclitaxel. J Natl Cancer Inst, 1996. 88(18): p. 1308-1314. 
 
 
134 
 
111. Symmans, W.F., et al., Paclitaxel-induced Apoptosis and Mitotic Arrest Assessed 
by Serial Fine-Needle Aspiration: Implications for Early Prediction of Breast 
Cancer Response to Neoadjuvant Treatment. Clin Cancer Res, 2000. 6(12): p. 
4610-4617. 
 
 
112. Rattanasomboon, N., et al., Growth and enumeration of the meat spoilage 
bacterium Brochothrix thermosphacta. Int J Food Microbiol, 1999. 51(2-3): p. 
145-158. 
 
 
113. Sakai, K., et al., Change in nitrite conversion direction from oxidation to 
reduction in heterotrophic bacteria depending on the aeration conditions. J 
Ferment Bioeng, 1997. 84(1): p. 47-52. 
 
 
114. Luxo, C., et al., Tamoxifen induces ultrastructural alterations in membranes of 
Bacillus Stearothermophilus. Toxicol in Vitro. 17(5-6): p. 623-628. 
 
 
115. Fonseca, C., S. Simões, and R. Gaspar, Paclitaxel-loaded PLGA nanoparticles: 
preparation, physicochemical characterization and in vitro anti-tumoral activity. 
J Control Release, 2002. 83(2): p. 273-286. 
 
 
116. Danhier, F., et al., Paclitaxel-loaded PEGylated PLGA-based nanoparticles: In 
vitro and in vivo evaluation. J Control Release, 2009. 133(1): p. 11-17. 
 
 
117. Kim, S.C., et al., Sensitive HPLC method for quantitation of paclitaxel 
(Genexol®) in biological samples with application to preclinical 
pharmacokinetics and biodistribution. J Pharmaceut Biomed Anal, 2005. 39(1-2): 
p. 170-176. 
 
 
118. Matsumoto, M. and K. Tanaka, Nano bubble--Size dependence of surface tension 
and inside pressure. Fluid Dynam Res. 40(7-8): p. 546-553. 
 
 
119. Whitby, C.P., D. Fornasiero, and J. Ralston, Effect of adding anionic surfactant 
on the stability of Pickering emulsions. J Colloid Interface Sci, 2009. 329(1): p. 
173-181. 
 
 
120. Aveyard, R., B.P. Binks, and J.H. Clint, Emulsions stabilised solely by colloidal 
particles. Adv Colloid Interface Sci, 2003. 100-102: p. 503-546. 
135 
 
 
 
121. Prestidge, C.A., T. Barnes, and S. Simovic, Polymer and particle adsorption at 
the PDMS droplet-water interface. Adv Colloid Interface Sci, 2004. 108-109: p. 
105-118. 
 
 
122. Hunter, T.N., et al., The role of particles in stabilising foams and emulsions. Adv  
Colloid  Interface Sci, 2008. 137(2): p. 57-81. 
 
 
123. Gonzenbach, U.T., et al., Ultrastable Particle-Stabilized Foams. Angew Chem Int 
Ed, 2006. 45(21): p. 3526-3530. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
136 
 
 
 
 
 
 
 
